BRPI0917470A2 - anticorpos humanos que se ligam ao gene de ativação linfocitária-3(lag) e usos dos mesmos - Google Patents

anticorpos humanos que se ligam ao gene de ativação linfocitária-3(lag) e usos dos mesmos

Info

Publication number
BRPI0917470A2
BRPI0917470A2 BRPI0917470A BRPI0917470A BRPI0917470A2 BR PI0917470 A2 BRPI0917470 A2 BR PI0917470A2 BR PI0917470 A BRPI0917470 A BR PI0917470A BR PI0917470 A BRPI0917470 A BR PI0917470A BR PI0917470 A2 BRPI0917470 A2 BR PI0917470A2
Authority
BR
Brazil
Prior art keywords
lag
bind
human antibodies
lymphocyte activation
activation gene
Prior art date
Application number
BRPI0917470A
Other languages
English (en)
Inventor
Alan J Korman
Heidi Leblanc
Kent B Thudium
Kyra D Zens
Mark Selby
Mark Yamanaka
Original Assignee
Medarex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41669613&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0917470(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Medarex Inc filed Critical Medarex Inc
Publication of BRPI0917470A2 publication Critical patent/BRPI0917470A2/pt
Publication of BRPI0917470B1 publication Critical patent/BRPI0917470B1/pt
Publication of BRPI0917470B8 publication Critical patent/BRPI0917470B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
BRPI0917470A 2008-08-11 2009-08-11 anticorpo anti-lag-3 ou uma porção de ligação ao antígeno do mesmo, seu método de preparação, seus usos, composição, imunoconjugado, molécula de ácido nucleico isolado, vetor de expressão e método de estímulo de uma resposta de células t antígenoespecífica BRPI0917470B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18854808P 2008-08-11 2008-08-11
US61/188,548 2008-08-11
PCT/US2009/053405 WO2010019570A2 (en) 2008-08-11 2009-08-11 Human antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof

Publications (3)

Publication Number Publication Date
BRPI0917470A2 true BRPI0917470A2 (pt) 2015-12-01
BRPI0917470B1 BRPI0917470B1 (pt) 2020-09-24
BRPI0917470B8 BRPI0917470B8 (pt) 2021-05-25

Family

ID=41669613

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0917470A BRPI0917470B8 (pt) 2008-08-11 2009-08-11 anticorpo anti-lag-3 ou uma porção de ligação ao antígeno do mesmo, seu método de preparação, seus usos, composição, imunoconjugado, molécula de ácido nucleico isolado, vetor de expressão e método de estímulo de uma resposta de células t antígenoespecífica

Country Status (32)

Country Link
US (13) US20110150892A1 (pt)
EP (4) EP2320940B1 (pt)
JP (6) JP5647981B2 (pt)
KR (6) KR102121141B1 (pt)
CN (4) CN102176921B (pt)
AR (3) AR072999A1 (pt)
AU (2) AU2009282134B2 (pt)
BR (1) BRPI0917470B8 (pt)
CA (1) CA2734335C (pt)
CL (4) CL2011000308A1 (pt)
CO (1) CO6351751A2 (pt)
CY (2) CY1116582T1 (pt)
DK (3) DK2320940T3 (pt)
EA (2) EA201590777A1 (pt)
ES (3) ES2537203T3 (pt)
HK (2) HK1151985A1 (pt)
HR (3) HRP20221191T1 (pt)
HU (2) HUE025250T2 (pt)
IL (4) IL210731A (pt)
LT (2) LT2905030T (pt)
MX (2) MX2011001250A (pt)
NZ (3) NZ602780A (pt)
PE (3) PE20190373A1 (pt)
PL (3) PL2320940T3 (pt)
PT (3) PT2905030T (pt)
SG (1) SG10201706497QA (pt)
SI (2) SI2320940T1 (pt)
SM (1) SMT201500125B (pt)
TN (1) TN2011000025A1 (pt)
TW (1) TWI491408B (pt)
WO (1) WO2010019570A2 (pt)
ZA (1) ZA201101009B (pt)

Families Citing this family (593)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1957539B1 (en) 2005-12-08 2013-04-17 Medarex, Inc. Human monoclonal antibodies to protein tyrosine kinase 7 (ptk7) and their use
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
CN103429737B (zh) 2010-11-30 2020-07-14 中外制药株式会社 细胞毒诱导治疗剂
US8440797B2 (en) 2010-12-06 2013-05-14 Dainippon Sumitomo Pharma Co., Ltd. Human monoclonal antibody
CA2820134A1 (en) * 2010-12-06 2012-06-14 Dainippon Sumitomo Pharma Co., Ltd. Human monoclonal antibody
CN107988156B (zh) 2011-06-30 2022-01-04 建新公司 T细胞活化的抑制剂
US9416132B2 (en) 2011-07-21 2016-08-16 Tolero Pharmaceuticals, Inc. Substituted imidazo[1,2-b]pyridazines as protein kinase inhibitors
AR091649A1 (es) * 2012-07-02 2015-02-18 Bristol Myers Squibb Co Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos
EP4163387A1 (en) 2013-03-15 2023-04-12 The University of Chicago Methods and compositions related to t-cell activity
PL2970464T3 (pl) * 2013-03-15 2020-10-05 Glaxosmithkline Intellectual Property Development Limited Wiążące białka anty-lag-3
TWI654206B (zh) 2013-03-16 2019-03-21 諾華公司 使用人類化抗－ｃｄ１９嵌合抗原受體治療癌症
DK2992017T3 (da) 2013-05-02 2021-01-25 Anaptysbio Inc Antistoffer rettet mod programmeret død-1 (pd-1)
KR20160037989A (ko) 2013-08-02 2016-04-06 아두로 바이오테크 홀딩스, 유럽 비.브이. 면역 자극을 위한 cd27 효능제와 면역 체크포인트 억제의 조합
DK3030262T3 (da) 2013-08-08 2019-12-02 Cytune Pharma Kombineret farmaceutisk sammensætning
EP4269441A3 (en) 2013-08-08 2024-01-24 Cytune Pharma Il-15 and il-15ralpha sushi domain based on modulokines
AU2014323523B2 (en) * 2013-09-20 2020-02-20 Bristol-Myers Squibb Company Combination of anti-LAG-3 antibodies and anti-PD-1 antibodies to treat tumors
US10781242B2 (en) 2013-09-24 2020-09-22 Medicenna Therapeutics Inc. Interleukin-2 fusion proteins and uses thereof
EP3757130A1 (en) 2013-09-26 2020-12-30 Costim Pharmaceuticals Inc. Methods for treating hematologic cancers
WO2015066413A1 (en) 2013-11-01 2015-05-07 Novartis Ag Oxazolidinone hydroxamic acid compounds for the treatment of bacterial infections
US20150210772A1 (en) * 2013-12-17 2015-07-30 Genentech, Inc. Methods of treating cancer using pd-1 axis binding antagonists and an anti-cd20 antibody
AU2014364601A1 (en) * 2013-12-17 2016-07-07 Genentech, Inc. Methods of treating HER2-positive cancers using PD-1 axis binding antagonists and anti-HER2 antibodies
GB201322626D0 (en) 2013-12-19 2014-02-05 Immutep S A Combined preparations for the treatment of cancer
US10640569B2 (en) 2013-12-19 2020-05-05 Novartis Ag Human mesothelin chimeric antigen receptors and uses thereof
EP3466949B1 (en) 2013-12-24 2020-12-23 Bristol-Myers Squibb Company Tricyclic compound as anticancer agents
JO3517B1 (ar) 2014-01-17 2020-07-05 Novartis Ag ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
EP3099716A1 (en) * 2014-01-28 2016-12-07 Bristol-Myers Squibb Company Anti-lag-3 antibodies to treat hematological malignancies
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
US9394365B1 (en) 2014-03-12 2016-07-19 Yeda Research And Development Co., Ltd Reducing systemic regulatory T cell levels or activity for treatment of alzheimer's disease
US10618963B2 (en) 2014-03-12 2020-04-14 Yeda Research And Development Co. Ltd Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
US10519237B2 (en) 2014-03-12 2019-12-31 Yeda Research And Development Co. Ltd Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
RU2690670C2 (ru) 2014-03-12 2019-06-05 Ида Рисерч Энд Дивелопмент Ко., Лтд Снижение уровней или активности системных регуляторных т-клеток для лечения заболевания или повреждения цнс
KR20220126813A (ko) * 2014-03-14 2022-09-16 노파르티스 아게 Lag-3에 대한 항체 분자 및 그의 용도
EP3593812A3 (en) 2014-03-15 2020-05-27 Novartis AG Treatment of cancer using chimeric antigen receptor
UA121383C2 (uk) 2014-03-24 2020-05-25 Новартіс Аг Органічні сполуки, що є монобактамами, для лікування бактеріальних інфекцій
TWI726842B (zh) 2014-04-07 2021-05-11 日商中外製藥股份有限公司 免疫活化抗原結合分子
RU2718542C2 (ru) 2014-04-07 2020-04-08 Новартис Аг Лечение злокачественной опухоли с использованием химерного рецептора антигена против cd19
WO2015164815A1 (en) 2014-04-24 2015-10-29 The Board Of Trustees Of The Leland Stanford Junior University Superagonists, partial agonists and antagonists of interleukin-2
EP3144388B1 (en) 2014-05-13 2020-07-01 Chugai Seiyaku Kabushiki Kaisha T cell-redirecting antigen-binding molecule for cells having immunosuppression function
DK3248986T3 (da) 2014-05-16 2022-04-04 Ablynx Nv Variable immunoglobulindomæner
SG10201810124PA (en) 2014-05-16 2018-12-28 Ablynx Nv Improved immunoglobulin variable domains
US10155818B2 (en) 2014-05-28 2018-12-18 Agenus Inc. Anti-GITR antibodies and methods of use thereof
PE20170441A1 (es) 2014-06-06 2017-04-26 Bristol Myers Squibb Co Anticuerpos contra el receptor del factor de necrosis tumoral inducido por glucocorticoides (gitr) y sus usos
JP2017525753A (ja) 2014-06-06 2017-09-07 フレクサス・バイオサイエンシーズ・インコーポレイテッドＦｌｅｘｕｓ Ｂｉｏｓｃｉｅｎｃｅｓ， Ｉｎｃ． 免疫調節剤
TWI693232B (zh) * 2014-06-26 2020-05-11 美商宏觀基因股份有限公司 與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法
US11542488B2 (en) 2014-07-21 2023-01-03 Novartis Ag Sortase synthesized chimeric antigen receptors
MX2017001008A (es) 2014-07-21 2017-08-02 Novartis Ag Tratamiento de cancer utilizando un receptor quimerico de antigeno cd33.
JP2017528433A (ja) 2014-07-21 2017-09-28 ノバルティス アーゲー 低い免疫増強用量のｍＴＯＲ阻害剤とＣＡＲの組み合わせ
EP3174546B1 (en) 2014-07-31 2019-10-30 Novartis AG Subset-optimized chimeric antigen receptor-containing t-cells
US10160726B2 (en) 2014-08-06 2018-12-25 Novartis Ag Quinolone derivatives as antibacterials
EP3646879B1 (en) 2014-08-12 2024-04-03 Massachusetts Institute Of Technology Synergistic tumor treatment with integrin-binding-fc-fusion protein and an immune checkpoint inhibitor
WO2016025645A1 (en) 2014-08-12 2016-02-18 Massachusetts Institute Of Technology Synergistic tumor treatment with il-2, a therapeutic antibody, and an immune checkpoint blocker
WO2016025880A1 (en) 2014-08-14 2016-02-18 Novartis Ag Treatment of cancer using gfr alpha-4 chimeric antigen receptor
JO3663B1 (ar) 2014-08-19 2020-08-27 Merck Sharp & Dohme الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
MY189028A (en) 2014-08-19 2022-01-20 Novartis Ag Anti-cd123 chimeric antigen receptor (car) for use in cancer treatment
EP3659621A1 (en) 2014-09-13 2020-06-03 Novartis AG Combination therapies for cancer
BR112017005390A2 (pt) 2014-09-17 2017-12-12 Novartis Ag células citotóxicas alvo com receptores quiméricos para imunoterapia adotiva
BR112017006664A2 (pt) 2014-10-03 2017-12-26 Novartis Ag terapias de combinação
KR20170068504A (ko) 2014-10-08 2017-06-19 노파르티스 아게 키메라 항원 수용체 요법에 대한 치료 반응성을 예측하는 바이오마커 및 그의 용도
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
CN115040532A (zh) 2014-10-10 2022-09-13 伊黛拉制药有限公司 使用tlr9激动剂与检查点抑制剂对癌症的治疗
US9988452B2 (en) 2014-10-14 2018-06-05 Novartis Ag Antibody molecules to PD-L1 and uses thereof
CN107205970A (zh) 2014-11-05 2017-09-26 弗莱塞斯生物科学公司 免疫调节剂
AR102537A1 (es) 2014-11-05 2017-03-08 Flexus Biosciences Inc Agentes inmunomoduladores
UY36390A (es) 2014-11-05 2016-06-01 Flexus Biosciences Inc Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido), sus métodos de síntesis y composiciones farmacéuticas que los contienen
MX2017006323A (es) 2014-11-21 2017-08-21 Bristol Myers Squibb Co Anticuerpos que comprenden regiones constantes pesadas modificadas.
CN113773388A (zh) 2014-11-21 2021-12-10 百时美施贵宝公司 抗cd73抗体及其用途
WO2016090034A2 (en) 2014-12-03 2016-06-09 Novartis Ag Methods for b cell preconditioning in car therapy
WO2016094639A1 (en) 2014-12-10 2016-06-16 Wisconsin Alumni Research Foundation Mini-intronic plasmid dna vaccines in combination with lag3 blockade
AU2015365455B2 (en) 2014-12-16 2019-01-17 Novartis Ag Isoxazole hydroxamic acid compounds as LpxC inhibitors
WO2016100882A1 (en) 2014-12-19 2016-06-23 Novartis Ag Combination therapies
AR103232A1 (es) 2014-12-22 2017-04-26 Bristol Myers Squibb Co ANTAGONISTAS DE TGFbR
KR102644115B1 (ko) 2014-12-23 2024-03-05 브리스톨-마이어스 스큅 컴퍼니 Tigit에 대한 항체
GB201500374D0 (en) * 2015-01-09 2015-02-25 Immutep S A Combined preparations for the treatment of cancer
US11161907B2 (en) 2015-02-02 2021-11-02 Novartis Ag Car-expressing cells against multiple tumor antigens and uses thereof
MA41463A (fr) * 2015-02-03 2017-12-12 Anaptysbio Inc Anticorps dirigés contre le gène d'activation 3 des lymphocytes (lag-3)
WO2016127052A1 (en) 2015-02-05 2016-08-11 Bristol-Myers Squibb Company Cxcl11 and smica as predictive biomarkers for efficacy of anti-ctla4 immunotherapy
ES2789331T3 (es) 2015-03-02 2020-10-26 Rigel Pharmaceuticals Inc Inhibidores de TGF-beta
JP6692826B2 (ja) 2015-03-10 2020-05-13 アドゥロ バイオテック，インク． 「インターフェロン遺伝子刺激因子」依存性シグナル伝達の活性化のための組成物及び方法
US20180133327A1 (en) 2015-03-16 2018-05-17 Amal Therapeutics Sa Cell Penetrating Peptides and Complexes Comprising the Same
SG11201708097SA (en) 2015-04-03 2017-10-30 Bristol Myers Squibb Co Inhibitors of indoleamine 2,3-dioxygenase for the treatment of cancer
US20180140602A1 (en) 2015-04-07 2018-05-24 Novartis Ag Combination of chimeric antigen receptor therapy and amino pyrimidine derivatives
SI3280729T1 (sl) 2015-04-08 2022-09-30 Novartis Ag Terapije CD20, terapije CD22 in kombinacija terapij s celico, ki izraža himerni antigenski receptor CD19 (CAR)
TW201642897A (zh) 2015-04-08 2016-12-16 Ｆ 星生物科技有限公司 Ｈｅｒ２結合劑治療
BR112017020952A2 (pt) 2015-04-13 2018-07-10 Five Prime Therapeutics Inc método de tratamento de câncer, composição e uso da composição
EP4234685A3 (en) 2015-04-17 2023-09-06 Novartis AG Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells
EA201792273A1 (ru) 2015-04-17 2018-04-30 Бристол-Маерс Сквибб Компани Композиции, содержащие комбинацию анти-pd-1 антитела и другого антитела
WO2016172583A1 (en) 2015-04-23 2016-10-27 Novartis Ag Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
WO2016177682A1 (en) 2015-05-06 2016-11-10 Snipr Technologies Limited Altering microbial populations & modifying microbiota
US10683290B2 (en) 2015-05-11 2020-06-16 Bristol-Myers Squibb Company Tricyclic compounds as anticancer agents
US10174024B2 (en) 2015-05-12 2019-01-08 Bristol-Myers Squibb Company 5H-pyrido[3,2-B]indole compounds as anticancer agents
US9725449B2 (en) 2015-05-12 2017-08-08 Bristol-Myers Squibb Company Tricyclic compounds as anticancer agents
LT3303394T (lt) 2015-05-29 2020-10-12 Agenus Inc. Anti-ctla-4 antikūnai ir jų naudojimo būdai
HUE061253T2 (hu) 2015-05-29 2023-06-28 Bristol Myers Squibb Co Antitestek OX40 ellen és azok felhasználásai
EA039293B1 (ru) * 2015-06-05 2021-12-30 Мерк Шарп И Доум Корп. Антитела против lag3 и антигенсвязывающие фрагменты
TWI773646B (zh) * 2015-06-08 2022-08-11 美商宏觀基因股份有限公司 結合lag-3的分子和其使用方法
MA42270A (fr) 2015-06-24 2018-05-02 Janssen Biotech Inc Modulation immunitaire et traitement de tumeurs solides avec des anticorps se liant spécifiquement à cd38
CN107922500A (zh) 2015-06-29 2018-04-17 洛克菲勒大学 具有增强的激动剂活性的抗cd40抗体
JP2018522887A (ja) 2015-07-14 2018-08-16 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 免疫チェックポイント阻害剤を使用する癌の処置法
BR112018000903A2 (pt) 2015-07-16 2018-09-11 Biokine Therapeutics Ltd. composições e métodos para o tratamento de câncer
CA2992551A1 (en) 2015-07-21 2017-01-26 Novartis Ag Methods for improving the efficacy and expansion of immune cells
US9902772B2 (en) * 2015-07-22 2018-02-27 Sorrento Therapeutics, Inc. Antibody therapeutics that bind LAG3
WO2017019757A1 (en) 2015-07-28 2017-02-02 Bristol-Myers Squibb Company Tgf beta receptor antagonists
PL3317301T3 (pl) 2015-07-29 2021-11-15 Novartis Ag Terapie skojarzone zawierające cząsteczki przeciwciał przeciw lag-3
EP3878465A1 (en) 2015-07-29 2021-09-15 Novartis AG Combination therapies comprising antibody molecules to tim-3
KR20180093127A (ko) 2015-07-30 2018-08-20 마크로제닉스, 인크. Pd-1-결합 분자 및 그것의 사용 방법
US20180230431A1 (en) 2015-08-07 2018-08-16 Glaxosmithkline Intellectual Property Development Limited Combination Therapy
JP2018525415A (ja) 2015-08-25 2018-09-06 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｔｇｆベータ受容体アンタゴニスト
PE20181322A1 (es) 2015-09-01 2018-08-14 Agenus Inc Anticuerpo anti-pd1 y sus metodos de uso
KR20180042412A (ko) 2015-09-02 2018-04-25 이뮤텝 에스.에이.에스. 항-lag-3 항체
EP3344996A2 (en) 2015-09-03 2018-07-11 The Trustees Of The University Of Pennsylvania Biomarkers predictive of cytokine release syndrome
KR102146319B1 (ko) 2015-10-02 2020-08-25 에프. 호프만-라 로슈 아게 Pd1 및 tim3에 특이적인 이중특이성 항체
TWI756187B (zh) * 2015-10-09 2022-03-01 美商再生元醫藥公司 抗ｌａｇ３抗體及其用途
US10149887B2 (en) 2015-10-23 2018-12-11 Canbas Co., Ltd. Peptides and peptidomimetics in combination with t cell activating and/or checkpoint inhibiting agents for cancer treatment
CR20180306A (es) 2015-11-02 2018-10-16 Five Prime Therapeutics Inc Polipéptidos del dominio extracelular de cd80 y su uso en el tratamiento del cáncer
RS63125B1 (sr) 2015-11-03 2022-05-31 Janssen Biotech Inc Antitela koja se specifično vezuju za pd-1 i njihova upotreba
CA3004530A1 (en) 2015-11-07 2017-05-11 Multivir Inc. Methods and compositions comprising tumor suppressor gene therapy and immune checkpoint blockade for the treatment of cancer
JP6945456B2 (ja) * 2015-11-13 2021-10-06 マクロジェニクス，インコーポレーテッド Ｌａｇ‐３結合分子及びその使用方法
JP6931329B2 (ja) 2015-11-18 2021-09-01 中外製薬株式会社 免疫抑制機能を有する細胞に対するｔ細胞リダイレクト抗原結合分子を用いた併用療法
AU2016355570B2 (en) * 2015-11-18 2020-01-02 Merck Sharp & Dohme Llc PD1 and/or LAG3 binders
JP6925278B2 (ja) 2015-11-18 2021-08-25 中外製薬株式会社 液性免疫応答の増強方法
KR20180082563A (ko) 2015-11-19 2018-07-18 브리스톨-마이어스 스큅 컴퍼니 글루코코르티코이드-유도된 종양 괴사 인자 수용체 (gitr)에 대한 항체 및 그의 용도
WO2017087901A2 (en) * 2015-11-19 2017-05-26 Sutro Biopharma, Inc. Anti-lag3 antibodies, compositions comprising anti-lag3 antibodies and methods of making and using anti-lag3 antibodies
CN108366548B (zh) 2015-11-20 2021-10-08 瑞泽恩制药公司 具有人源化淋巴细胞活化基因3的非人动物
RU2021107536A (ru) 2015-11-23 2021-07-02 Файв Прайм Терапьютикс, Инк. Ингибиторы fgfr2 отдельно или в комбинации с иммуностимулирующими агентами в лечении рака
MX2018006477A (es) 2015-12-02 2018-09-03 Agenus Inc Anticuerpos y metodos de uso de estos.
US10954301B2 (en) 2015-12-14 2021-03-23 Macrogenics, Inc. Bispecific molecules having immunoreactivity with PD-1 and CTLA-4, and methods of use thereof
JP6856648B2 (ja) 2015-12-15 2021-04-07 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｃｘｃｒ４受容体アンタゴニスト
WO2017106129A1 (en) * 2015-12-16 2017-06-22 Merck Sharp & Dohme Corp. Anti-lag3 antibodies and antigen-binding fragments
AU2016369537B2 (en) 2015-12-17 2024-03-14 Novartis Ag Antibody molecules to PD-1 and uses thereof
US10392442B2 (en) 2015-12-17 2019-08-27 Bristol-Myers Squibb Company Use of anti-PD-1 antibody in combination with anti-CD27 antibody in cancer treatment
WO2017106630A1 (en) 2015-12-18 2017-06-22 The General Hospital Corporation Polyacetal polymers, conjugates, particles and uses thereof
WO2017103895A1 (en) 2015-12-18 2017-06-22 Novartis Ag Antibodies targeting cd32b and methods of use thereof
EP3393504A1 (en) 2015-12-22 2018-10-31 Novartis AG Mesothelin chimeric antigen receptor (car) and antibody against pd-l1 inhibitor for combined use in anticancer therapy
EP3402819A1 (en) 2016-01-11 2018-11-21 Novartis AG Immune-stimulating humanized monoclonal antibodies against human interleukin-2, and fusion proteins thereof
KR20180110131A (ko) 2016-02-19 2018-10-08 노파르티스 아게 항바이러스제로서의 테트라시클릭 피리돈 화합물
AU2017228470A1 (en) 2016-03-04 2018-08-30 Bristol-Myers Squibb Company Combination therapy with anti-CD73 antibodies
CA3016287A1 (en) 2016-03-04 2017-09-08 Novartis Ag Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore
SG10201601719RA (en) * 2016-03-04 2017-10-30 Agency Science Tech & Res Anti-LAG-3 Antibodies
CA3016474A1 (en) 2016-03-15 2017-09-21 Mersana Therapeutics, Inc. Napi2b-targeted antibody-drug conjugates and methods of use thereof
FI3429618T3 (fi) 2016-03-16 2024-03-15 Amal Therapeutics Sa Immuunijäjestelmän tarkistuspisteen modulaattorin ja soluun tunkeutuvan peptidin, cargon ja tlr-peptidiagonistin kompleksin yhdistelmä lääketieteelliseen käyttöön
CN109311885A (zh) 2016-03-24 2019-02-05 诺华股份有限公司 炔基核苷类似物作为人类鼻病毒的抑制剂
MX2018012488A (es) 2016-04-13 2019-06-06 Vivia Biotech Sl Linfocitos t activados por bite ex vivo.
EA201892362A1 (ru) 2016-04-18 2019-04-30 Селлдекс Терапьютикс, Инк. Агонистические антитела, которые связываются с cd40 человека, и варианты их применения
CN109415320A (zh) 2016-05-04 2019-03-01 百时美施贵宝公司 吲哚胺2,3-双加氧酶的抑制剂及其使用方法
US10696648B2 (en) 2016-05-04 2020-06-30 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
WO2017192840A1 (en) 2016-05-04 2017-11-09 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
CN109311816A (zh) 2016-05-04 2019-02-05 百时美施贵宝公司 吲哚胺2,3-双加氧酶的抑制剂及其使用方法
CN109414421A (zh) 2016-05-04 2019-03-01 百时美施贵宝公司 吲哚胺2,3-双加氧酶的抑制剂及其使用方法
PL3458478T3 (pl) * 2016-05-18 2021-06-28 Boehringer Ingelheim International Gmbh Przeciwciała anty pd-1 i anty-lag3 do leczenia nowotworu
US11623958B2 (en) 2016-05-20 2023-04-11 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
AU2017266951B2 (en) 2016-05-20 2021-05-27 Biohaven Pharmaceutical Holding Company Ltd. Use of Glutamate modulating agents with Immunotherapies to treat cancer
WO2017205875A1 (en) 2016-05-27 2017-11-30 Dnatrix, Inc. Adenovirus and immunomodulator combination therapy
CN109310763B (zh) 2016-06-10 2022-10-21 Io治疗公司 用于癌症免疫疗法的受体选择性类视黄醇和rexinoid化合物和免疫调节剂
WO2017218533A1 (en) 2016-06-13 2017-12-21 Torque Therapeutics, Inc. Methods and compositions for promoting immune cell function
DK3468957T3 (da) 2016-06-14 2020-09-14 Novartis Ag Krystallinsk form af (r)-4-(5-(cyclopro pylethynyl)isoxazol-3-yl)-n-hydroxy-2-methyl-2-(methylsulfonyl)butanamid som et antibakterielt middel
WO2017216685A1 (en) 2016-06-16 2017-12-21 Novartis Ag Pentacyclic pyridone compounds as antivirals
WO2017216686A1 (en) 2016-06-16 2017-12-21 Novartis Ag 8,9-fused 2-oxo-6,7-dihydropyrido-isoquinoline compounds as antivirals
BR112018076525A2 (pt) * 2016-06-20 2019-04-02 F-Star Beta Limited membros de ligação a lag-3
PL3472207T3 (pl) * 2016-06-20 2021-07-12 F-Star Delta Limited Wiążące cząsteczki wiążące się z PD-L1 i LAG-3
CN109475603B (zh) 2016-06-20 2023-06-13 科马布有限公司 抗pd-l1抗体
JP6998895B2 (ja) * 2016-06-23 2022-01-18 江蘇恒瑞医薬股▲ふん▼有限公司 Ｌａｇ－３抗体、その抗原結合フラグメント、およびそれらの医薬的用途
JP7054681B2 (ja) 2016-06-24 2022-04-14 インフィニティー ファーマシューティカルズ， インコーポレイテッド 組合せ療法
EP3478321A4 (en) 2016-06-30 2020-04-22 Oncorus, Inc. PSEUDOTYPIZED ONCOLYTIC VIRAL ADMINISTRATION OF THERAPEUTIC POLYPEPTIDES
WO2018009466A1 (en) 2016-07-05 2018-01-11 Aduro Biotech, Inc. Locked nucleic acid cyclic dinucleotide compounds and uses thereof
CN109757103B (zh) 2016-07-14 2024-01-02 百时美施贵宝公司 针对tim3的抗体及其用途
GB201612520D0 (en) 2016-07-19 2016-08-31 F-Star Beta Ltd Binding molecules
CN109641947B (zh) 2016-07-20 2023-04-14 犹他大学研究基金会 Cd229 car t细胞及其使用方法
US20190292179A1 (en) 2016-07-21 2019-09-26 Bristol-Myers Squibb Company TGF Beta RECEPTOR ANTAGONISTS
EA039718B1 (ru) * 2016-07-21 2022-03-03 Регенерон Фармасьютикалз, Инк. Антитела к lag3 и их применения
KR102340687B1 (ko) 2016-08-15 2021-12-16 국립대학법인 홋가이도 다이가쿠 항 lag-3 항체
AU2017313405A1 (en) 2016-08-17 2019-02-28 Compugen Ltd. Anti-TIGIT antibodies, anti-PVRIG antibodies and combinations thereof
US11351164B2 (en) 2016-08-26 2022-06-07 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
TW201811788A (zh) 2016-09-09 2018-04-01 瑞士商諾華公司 作為抗病毒劑之多環吡啶酮化合物
JP7256116B2 (ja) 2016-09-19 2023-04-11 アイ－エムエービー バイオファーマ （ハンジョウ） カンパニー リミテッド 抗ｇｍ－ｃｓｆ抗体およびその使用
KR20190057345A (ko) 2016-09-21 2019-05-28 아말 테라퓨틱스 에스에이 암 치료를 위한, 세포 투과 펩타이드, 멀티 에피토프 및 tlr 펩타이드 작용제를 포함하는 융합체
WO2018057955A1 (en) 2016-09-23 2018-03-29 Elstar Therapeutics, Inc. Multispecific antibody molecules comprising lambda and kappa light chains
AU2017335732A1 (en) 2016-09-27 2019-04-04 Board Of Regents, The University Of Texas System Methods for enhancing immune checkpoint blockade therapy by modulating the microbiome
JOP20190061A1 (ar) 2016-09-28 2019-03-26 Novartis Ag مثبطات بيتا-لاكتاماز
CA3039646A1 (en) 2016-10-07 2018-04-12 Novartis Ag Chimeric antigen receptors for the treatment of cancer
US10844119B2 (en) 2016-10-11 2020-11-24 Agenus Inc. Anti-LAG-3 antibodies and methods of use thereof
US11278592B2 (en) 2016-10-12 2022-03-22 Board Of Regents, The University Of Texas System Methods and compositions for TUSC2 immunotherapy
UA127050C2 (uk) * 2016-10-13 2023-03-29 Чіа Тай Тяньцин Фармасьютікал Груп Ко., Лтд. Ahtи-lag-3 антитіло i композиція, що містить його
WO2018073753A1 (en) 2016-10-18 2018-04-26 Novartis Ag Fused tetracyclic pyridone compounds as antivirals
BR112019008859A2 (pt) 2016-11-01 2019-07-09 Anaptysbio Inc anticorpos direcionados contra a morte programada 1 (pd-1)
UY37463A (es) 2016-11-02 2018-05-31 Glaxosmithkline Ip No 2 Ltd Proteínas de unión
US10660909B2 (en) 2016-11-17 2020-05-26 Syntrix Biosystems Inc. Method for treating cancer using chemokine antagonists
US11279694B2 (en) 2016-11-18 2022-03-22 Sumitomo Dainippon Pharma Oncology, Inc. Alvocidib prodrugs and their use as protein kinase inhibitors
US11135307B2 (en) 2016-11-23 2021-10-05 Mersana Therapeutics, Inc. Peptide-containing linkers for antibody-drug conjugates
BR112019010878A2 (pt) 2016-11-29 2019-10-01 Lindhofer Horst combinação de anticorpos multifuncionais de redirecionamento de células t com moduladores de ponto de verificação imunológico e usos dos mesmos
AU2017368332A1 (en) 2016-12-03 2019-06-13 Juno Therapeutics, Inc. Methods for modulation of CAR-T cells
WO2018106738A1 (en) 2016-12-05 2018-06-14 Massachusetts Institute Of Technology Brush-arm star polymers, conjugates and particles, and uses thereof
IL307242A (en) 2016-12-07 2023-11-01 Agenus Inc Anti-CTLA-4 antibodies and methods of using them
AU2017375958A1 (en) 2016-12-12 2019-07-04 Multivir Inc. Methods and compositions comprising viral gene therapy and an immune checkpoint inhibitor for treatment and prevention of cancer and infectious diseases
WO2018112266A1 (en) 2016-12-14 2018-06-21 The Board Of Trustees Of The Leland Stanford Junior University Il-13 superkine: immune cell targeting constructs and methods of use thereof
CN108204958A (zh) * 2016-12-19 2018-06-26 伊缪泰普有限公司 结合测定
US10961239B2 (en) 2017-01-05 2021-03-30 Bristol-Myers Squibb Company TGF beta receptor antagonists
SG11201906192SA (en) 2017-01-09 2019-08-27 Tesaro Inc Methods of treating cancer with anti-pd-1 antibodies
US10350266B2 (en) 2017-01-10 2019-07-16 Nodus Therapeutics, Inc. Method of treating cancer with a multiple integrin binding Fc fusion protein
AU2018207303A1 (en) 2017-01-10 2019-07-25 xCella Biosciences, Inc. Combination tumor treatment with an integrin-binding-Fc fusion protein and immune modulator
SI3570844T1 (sl) 2017-01-20 2024-01-31 Arcus Biosciences, Inc. Azolopirimidin za zdravljenje z rakom povezanih motenj
CN110650974B (zh) 2017-02-10 2024-04-19 瑞泽恩制药公司 用于免疫-pet成像的放射性标记的抗-lag3抗体
US20200291089A1 (en) 2017-02-16 2020-09-17 Elstar Therapeutics, Inc. Multifunctional molecules comprising a trimeric ligand and uses thereof
CA3051839A1 (en) 2017-02-17 2018-08-23 Bristol-Myers Squibb Company Antibodies to alpha-synuclein and uses thereof
JP6929951B2 (ja) 2017-02-22 2021-09-01 アイ−エムエービー バイオファーマ （ハンジョウ） カンパニー リミテッド 抗ｌａｇ−３抗体およびその使用
WO2018152687A1 (en) * 2017-02-22 2018-08-30 I-Mab Anti-lymphocyte activation gene-3 (lag-3) antibodies and uses thereof
US20180271996A1 (en) 2017-02-28 2018-09-27 Mersana Therapeutics, Inc. Combination therapies of her2-targeted antibody-drug conjugates
EP3601355A1 (en) 2017-03-31 2020-02-05 Bristol-Myers Squibb Company Methods of treating tumor
JP2020512357A (ja) 2017-03-31 2020-04-23 ファイブ プライム セラピューティクス， インコーポレイテッド 抗ｇｉｔｒ抗体を使用した癌の併用療法
CA3053357A1 (en) 2017-04-03 2018-10-11 F. Hoffmann-La Roche Ag Immunoconjugates of an anti-pd-1 antibody with a mutant il-2 or with il-15
CA3185303A1 (en) 2017-04-05 2018-10-11 Symphogen A/S Combination therapies targeting pd-a, tim-3, and lag-3
KR102408873B1 (ko) 2017-04-05 2022-06-15 에프. 호프만-라 로슈 아게 Pd1 및 lag3에 특이적으로 결합하는 이중특이적 항체
PL3606954T3 (pl) * 2017-04-05 2022-10-17 F. Hoffmann-La Roche Ag Przeciwciała anty-LAG3
TWI788340B (zh) 2017-04-07 2023-01-01 美商必治妥美雅史谷比公司 抗icos促效劑抗體及其用途
AU2018256406A1 (en) 2017-04-19 2019-10-17 Marengo Therapeutics, Inc. Multispecific molecules and uses thereof
SG11201909710XA (en) 2017-04-21 2019-11-28 Kyn Therapeutics Indole ahr inhibitors and uses thereof
BR112019022009A2 (pt) 2017-04-21 2020-05-12 Sillajen, Inc. Terapia de combinação de vírus vaccinia oncolítico e inibidor de ponto de verificação
JP2020517699A (ja) 2017-04-26 2020-06-18 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ ジスルフィド結合の還元を最小限にする抗体製造法
AR111419A1 (es) 2017-04-27 2019-07-10 Novartis Ag Compuestos fusionados de indazol piridona como antivirales
JP2020517695A (ja) * 2017-04-27 2020-06-18 テサロ， インコーポレイテッド リンパ球活性化遺伝子−３（ｌａｇ−３）に対する抗体薬およびそれらの使用
US20200055948A1 (en) 2017-04-28 2020-02-20 Novartis Ag Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
US20200385472A1 (en) 2017-04-28 2020-12-10 Elstar Therapeutics, Inc. Multispecific molecules comprising a non-immunoglobulin heterodimerization domain and uses thereof
UY37695A (es) 2017-04-28 2018-11-30 Novartis Ag Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
CN110546509A (zh) 2017-04-28 2019-12-06 戊瑞治疗有限公司 用cd80细胞外结构域多肽进行治疗的方法
US20200179511A1 (en) 2017-04-28 2020-06-11 Novartis Ag Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
AR111651A1 (es) 2017-04-28 2019-08-07 Novartis Ag Conjugados de anticuerpos que comprenden agonistas del receptor de tipo toll y terapias de combinación
AR111658A1 (es) 2017-05-05 2019-08-07 Novartis Ag 2-quinolinonas tricíclicas como agentes antibacteriales
EP3621642A4 (en) 2017-05-10 2021-01-06 Centrymed Pharmaceutical Inc HUMAN MONOCLONAL ANTIBODIES AGAINST LAG3 AND THEIR USES
CN110891974B (zh) 2017-05-12 2021-08-06 哈普恩治疗公司 间皮素结合蛋白质
WO2018209049A1 (en) 2017-05-12 2018-11-15 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
CN110869392A (zh) 2017-05-16 2020-03-06 百时美施贵宝公司 用抗gitr激动性抗体治疗癌症
PL3634417T3 (pl) 2017-05-17 2023-09-25 Arcus Biosciences, Inc. Pochodne chinazolino-pirazolowe do leczenia chorób związanych z nowotworem
CN116333129A (zh) 2017-05-25 2023-06-27 百时美施贵宝公司 包含经修饰的重链恒定区的抗体
WO2018219956A1 (en) 2017-05-29 2018-12-06 Gamamabs Pharma Cancer-associated immunosuppression inhibitor
BR112019021847A2 (pt) 2017-05-30 2020-06-02 Bristol-Myers Squibb Company Composições compreendendo um anticorpo anti-lag-3 ou um anticorpo anti-lag-3 e um anticorpo anti-pd-1 ou anti-pd-l1
KR20200010500A (ko) 2017-05-30 2020-01-30 브리스톨-마이어스 스큅 컴퍼니 항-lag-3 항체, pd-1 경로 억제제, 및 면역요법제의 조합을 포함하는 조성물
BR112019020610A2 (pt) 2017-05-30 2020-04-22 Bristol-Myers Squibb Company tratamento de tumores positivos para o lag-3
US20210246227A1 (en) 2017-05-31 2021-08-12 Elstar Therapeutics, Inc. Multispecific molecules that bind to myeloproliferative leukemia (mpl) protein and uses thereof
CN111344303A (zh) 2017-06-01 2020-06-26 Xencor股份有限公司 结合cd123和cd3的双特异性抗体
WO2018223004A1 (en) 2017-06-01 2018-12-06 Xencor, Inc. Bispecific antibodies that bind cd20 and cd3
CA3065120A1 (en) 2017-06-02 2018-12-06 Juno Therapeutics, Inc. Articles of manufacture and methods for treatment using adoptive cell therapy
WO2018229715A1 (en) 2017-06-16 2018-12-20 Novartis Ag Compositions comprising anti-cd32b antibodies and methods of use thereof
CA3067909A1 (en) 2017-06-19 2018-12-27 Medicenna Therapeutics Inc. Uses and methods for il-2 superagonists, agonists, and fusions thereof
WO2018234879A1 (en) 2017-06-22 2018-12-27 Novartis Ag USE OF IL-1β BINDING ANTIBODIES IN THE TREATMENT OF CANCER
EP3641812A1 (en) 2017-06-22 2020-04-29 Novartis AG Antibody molecules to cd73 and uses thereof
WO2018235056A1 (en) 2017-06-22 2018-12-27 Novartis Ag IL-1BETA BINDING ANTIBODIES FOR USE IN THE TREATMENT OF CANCER
CN111050791A (zh) 2017-06-27 2020-04-21 诺华股份有限公司 用于抗tim-3抗体的给药方案及其用途
CA3067602A1 (en) 2017-06-29 2019-01-03 Juno Therapeutics, Inc. Mouse model for assessing toxicities associated with immunotherapies
MX2019014885A (es) 2017-06-30 2020-02-13 Bristol Myers Squibb Co Formas amorfas y cristalinas de inhibidores de indolamina 2,3-dioxigenasa (ido).
BR112020000228A2 (pt) 2017-07-06 2020-07-14 Merus N.V. anticorpos que modulam uma atividade biológica expressa por célula
CN110914303B (zh) * 2017-07-13 2023-06-02 南京维立志博生物科技有限公司 结合lag-3的抗体及其用途
AU2018301810A1 (en) 2017-07-13 2020-01-23 Io Therapeutics, Inc. Receptor subtype and function selective retinoid and rexinoid compounds in combination with immune modulators for cancer immunotherapy
CA3070095A1 (en) 2017-07-20 2019-01-24 Novartis Ag Dosage regimens of anti-lag-3 antibodies and uses thereof
EP3658565B1 (en) 2017-07-28 2022-11-09 Bristol-Myers Squibb Company Cyclic dinucleotides as anticancer agents
WO2019035938A1 (en) 2017-08-16 2019-02-21 Elstar Therapeutics, Inc. MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF
BR112020003116A2 (pt) 2017-08-17 2020-08-04 Ikena Oncology, Inc. inibidores de ahr e usos dos mesmos
IL272697B2 (en) 2017-08-18 2023-12-01 Adastra Pharmaceuticals Inc A polymorphic form of TG02
KR20200042937A (ko) * 2017-08-30 2020-04-24 페인스 테라퓨틱스 인코포레이티드 항-lag-3 항체 및 이의 용도
KR20200039796A (ko) 2017-08-31 2020-04-16 브리스톨-마이어스 스큅 컴퍼니 항암제로서의 시클릭 디뉴클레오티드
JP7209697B2 (ja) 2017-08-31 2023-01-20 ブリストル－マイヤーズ スクイブ カンパニー 抗癌剤としての環状ジヌクレオチド
MX2020002262A (es) 2017-08-31 2020-07-20 Io Therapeutics Inc Agonistas selectivos de rar en combinacion con moduladores inmunitarios para inmunoterapia contra el cancer.
WO2019046500A1 (en) 2017-08-31 2019-03-07 Bristol-Myers Squibb Company CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS
WO2019055579A1 (en) 2017-09-12 2019-03-21 Tolero Pharmaceuticals, Inc. TREATMENT REGIME FOR CANCERS THAT ARE INSENSITIVE TO BCL-2 INHIBITORS USING THE MCL-1 ALVOCIDIB INHIBITOR
IL307995A (en) 2017-09-22 2023-12-01 Kymera Therapeutics Inc Protein compounds and their uses
WO2019060693A1 (en) 2017-09-22 2019-03-28 Kymera Therapeutics, Inc. CRBN LIGANDS AND USES THEREOF
BR112020006860A2 (pt) * 2017-10-05 2020-10-20 Daiichi Sankyo Company, Limited composição para depleção de células t citotóxicas
WO2019074822A1 (en) 2017-10-09 2019-04-18 Bristol-Myers Squibb Company INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS AND METHODS OF USE
US11203592B2 (en) 2017-10-09 2021-12-21 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
WO2019075090A1 (en) 2017-10-10 2019-04-18 Tilos Therapeutics, Inc. ANTI-LAP ANTIBODIES AND USES THEREOF
WO2019074887A1 (en) 2017-10-10 2019-04-18 Bristol-Myers Squibb Company CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS
EP3694884A1 (en) 2017-10-15 2020-08-19 Bristol-Myers Squibb Company Methods of treating tumor
WO2019079261A1 (en) 2017-10-16 2019-04-25 Bristol-Myers Squibb Company CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS
CN111094339B (zh) * 2017-10-17 2023-01-24 江苏恒瑞医药股份有限公司 抗pd-1抗体和抗lag-3抗体联合在制备治疗肿瘤的药物中的用途
WO2019077062A1 (en) 2017-10-18 2019-04-25 Vivia Biotech, S.L. C-CELLS ACTIVATED BY BIT
US20210040205A1 (en) 2017-10-25 2021-02-11 Novartis Ag Antibodies targeting cd32b and methods of use thereof
JP2021501801A (ja) 2017-11-01 2021-01-21 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 癌の処置に用いるための免疫刺激アゴニスト抗体
US20210132042A1 (en) 2017-11-01 2021-05-06 Juno Therapeutics, Inc. Methods of assessing or monitoring a response to a cell therapy
CA3082010A1 (en) 2017-11-01 2019-05-09 Juno Therapeutics, Inc. Chimeric antigen receptors specific for b-cell maturation antigen (bcma)
MA49911A (fr) 2017-11-01 2020-06-24 Juno Therapeutics Inc Anticorps et récepteurs antigéniques chimériques spécifiques de l'antigene de maturation des lymphocytes b
EP3707138B1 (en) 2017-11-06 2022-07-13 Bristol-Myers Squibb Company Isofuranone compounds useful as hpk1 inhibitors
CN111655288A (zh) 2017-11-16 2020-09-11 诺华股份有限公司 组合疗法
WO2019097479A1 (en) 2017-11-17 2019-05-23 Novartis Ag Novel dihydroisoxazole compounds and their use for the treatment of hepatitis b
WO2019104289A1 (en) 2017-11-27 2019-05-31 Mersana Therapeutics, Inc. Pyrrolobenzodiazepine antibody conjugates
CA3083949A1 (en) 2017-11-30 2020-06-06 Novartis Ag Bcma-targeting chimeric antigen receptor, and uses thereof
WO2019113464A1 (en) 2017-12-08 2019-06-13 Elstar Therapeutics, Inc. Multispecific molecules and uses thereof
US20210070845A1 (en) 2017-12-15 2021-03-11 Juno Therapeutics, Inc. Anti-cct5 binding molecules and methods of use thereof
CA3086098A1 (en) 2017-12-19 2019-06-27 F-Star Beta Limited Fc binding fragments comprising a pd-l1 antigen-binding site
JP2021507906A (ja) 2017-12-20 2021-02-25 ノバルティス アーゲー 抗ウイルス剤としての融合三環式ピラゾロ−ジヒドロピラジニル−ピリドン化合物
TW201929908A (zh) 2017-12-21 2019-08-01 美商梅爾莎納醫療公司 吡咯并苯并二氮呯抗體共軛物
JP2021506922A (ja) * 2017-12-22 2021-02-22 江蘇恒瑞医薬股▲ふん▼有限公司 Ｌａｇ−３抗体医薬組成物およびその使用
CN112105385A (zh) 2017-12-26 2020-12-18 凯麦拉医疗公司 Irak降解剂和其用途
CN109970856B (zh) * 2017-12-27 2022-08-23 信达生物制药(苏州)有限公司 抗lag-3抗体及其用途
WO2019133747A1 (en) 2017-12-27 2019-07-04 Bristol-Myers Squibb Company Anti-cd40 antibodies and uses thereof
CN115925943A (zh) * 2017-12-27 2023-04-07 信达生物制药(苏州)有限公司 抗pd-l1抗体及其用途
WO2019129137A1 (zh) * 2017-12-27 2019-07-04 信达生物制药(苏州)有限公司 抗lag-3抗体及其用途
WO2019133847A1 (en) 2017-12-29 2019-07-04 Oncorus, Inc. Oncolytic viral delivery of therapeutic polypeptides
US11447449B2 (en) 2018-01-05 2022-09-20 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
CN112218651A (zh) 2018-01-08 2021-01-12 诺华公司 用于与嵌合抗原受体疗法组合的免疫增强rna
US11485743B2 (en) 2018-01-12 2022-11-01 Kymera Therapeutics, Inc. Protein degraders and uses thereof
WO2019140387A1 (en) 2018-01-12 2019-07-18 Kymera Therapeutics, Inc. Crbn ligands and uses thereof
US20220089720A1 (en) 2018-01-12 2022-03-24 Bristol-Myers Squibb Company Antibodies against tim3 and uses thereof
CN111542546B (zh) * 2018-01-18 2022-08-16 四川科伦博泰生物医药股份有限公司 抗lag-3抗体及其用途
SG11202006832YA (en) 2018-01-29 2020-08-28 Merck Patent Gmbh Gcn2 inhibitors and uses thereof
US10988477B2 (en) 2018-01-29 2021-04-27 Merck Patent Gmbh GCN2 inhibitors and uses thereof
EP3746480A1 (en) 2018-01-31 2020-12-09 F. Hoffmann-La Roche AG Bispecific antibodies comprising an antigen-binding site binding to lag3
CN111630063A (zh) 2018-01-31 2020-09-04 豪夫迈·罗氏有限公司 稳定化的免疫球蛋白结构域
WO2019152660A1 (en) 2018-01-31 2019-08-08 Novartis Ag Combination therapy using a chimeric antigen receptor
US20210069246A1 (en) 2018-01-31 2021-03-11 Celgene Corporation Combination therapy using adoptive cell therapy and checkpoint inhibitor
US20200399383A1 (en) 2018-02-13 2020-12-24 Novartis Ag Chimeric antigen receptor therapy in combination with il-15r and il15
US10519187B2 (en) 2018-02-13 2019-12-31 Bristol-Myers Squibb Company Cyclic dinucleotides as anticancer agents
WO2019165315A1 (en) 2018-02-23 2019-08-29 Syntrix Biosystems Inc. Method for treating cancer using chemokine antagonists alone or in combination
EP3759110A1 (en) 2018-02-28 2021-01-06 Novartis AG Indole-2-carbonyl compounds and their use for the treatment of hepatitis b
US11795221B2 (en) 2018-02-28 2023-10-24 WuXi Biologics Ireland Limited Monoclonal antibody against human LAG-3, method for preparing the same, and use thereof
US11945834B2 (en) 2018-03-08 2024-04-02 Bristol-Myers Squibb Company Cyclic dinucleotides as anticancer agents
EP3765516A2 (en) 2018-03-14 2021-01-20 Elstar Therapeutics, Inc. Multifunctional molecules and uses thereof
US20210238280A1 (en) 2018-03-14 2021-08-05 Elstar Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
KR20200135986A (ko) 2018-03-19 2020-12-04 멀티비르 인코포레이티드 종양 억제인자 유전자 치료 및 cd122/cd132 작용제를 포함하는 암 치료를 위한 방법 및 조성물
EP3768720A4 (en) 2018-03-20 2022-01-05 Wuxi Biologics Ireland Limited NEW ANTI-LAG-3 ANTIBODY POLYPEPTIDE
SG11202008593PA (en) 2018-03-21 2020-10-29 Five Prime Therapeutics Inc ANTIBODIES BINDING TO VISTA AT ACIDIC pH
CA3093186A1 (en) * 2018-03-22 2019-09-26 Keires Ag Antagonistic antigen binding proteins
AU2019236865A1 (en) 2018-03-23 2020-10-01 Bristol-Myers Squibb Company Antibodies against MICA and/or MICB and uses thereof
US10760075B2 (en) 2018-04-30 2020-09-01 Snipr Biome Aps Treating and preventing microbial infections
SG11202009504YA (en) 2018-03-25 2020-10-29 Snipr Biome Aps Treating & preventing microbial infections
CN111971306A (zh) 2018-03-30 2020-11-20 百时美施贵宝公司 治疗肿瘤的方法
JP7104458B2 (ja) 2018-04-02 2022-07-21 上海博威生物医薬有限公司 リンパ球活性化遺伝子－３（ｌａｇ－３）結合抗体およびその使用
CN110343178B (zh) * 2018-04-03 2022-07-22 上海开拓者生物医药有限公司 抗人lag-3单克隆抗体及其应用
US20210147547A1 (en) 2018-04-13 2021-05-20 Novartis Ag Dosage Regimens For Anti-Pd-L1 Antibodies And Uses Thereof
CN112292128A (zh) 2018-04-16 2021-01-29 阿瑞斯医疗有限公司 Ep4抑制剂和其用途
JP2021521784A (ja) 2018-04-18 2021-08-30 ゼンコア インコーポレイテッド ＩＬ−１５／ＩＬ−１５ＲａＦｃ融合タンパク質とＰＤ−１抗原結合ドメインを含むＰＤ−１標的化ヘテロダイマー融合タンパク質およびそれらの使用
TW202011984A (zh) 2018-04-18 2020-04-01 美商山可爾股份有限公司 IL-15/IL-15Rα異二聚體Fc融合蛋白及其用途
US20210047405A1 (en) 2018-04-27 2021-02-18 Novartis Ag Car t cell therapies with enhanced efficacy
WO2019213282A1 (en) 2018-05-01 2019-11-07 Novartis Ag Biomarkers for evaluating car-t cells to predict clinical outcome
US20230339891A1 (en) 2018-05-03 2023-10-26 Bristol-Myers Squibb Company Uracil derivatives as mer-axl inhibitors
TW202015726A (zh) 2018-05-30 2020-05-01 瑞士商諾華公司 Ｅｎｔｐｄ２抗體、組合療法、及使用該等抗體和組合療法之方法
WO2019232244A2 (en) 2018-05-31 2019-12-05 Novartis Ag Antibody molecules to cd73 and uses thereof
US20210205449A1 (en) 2018-06-01 2021-07-08 Novartis Ag Dosing of a bispecific antibody that bind cd123 and cd3
EP3802611A2 (en) 2018-06-01 2021-04-14 Novartis AG Binding molecules against bcma and uses thereof
JP2021527082A (ja) * 2018-06-11 2021-10-11 イェール ユニバーシティーＹａｌｅ Ｕｎｉｖｅｒｓｉｔｙ 新規な免疫チェックポイント阻害剤
JP7438988B2 (ja) 2018-06-13 2024-02-27 ノバルティス アーゲー Ｂｃｍａキメラ抗原受容体及びその使用
CN110606892B (zh) * 2018-06-14 2023-09-26 华博生物医药技术（上海）有限公司 一种高亲和力高生物活性的lag-3抗体及其应用
CN110615840A (zh) * 2018-06-19 2019-12-27 信达生物制药(苏州)有限公司 全人源的抗lag-3抗体及其应用
US11180531B2 (en) 2018-06-22 2021-11-23 Bicycletx Limited Bicyclic peptide ligands specific for Nectin-4
CA3104654A1 (en) 2018-06-27 2020-01-02 Bristol-Myers Squibb Company Substituted naphthyridinone compounds useful as t cell activators
KR20210024587A (ko) 2018-06-27 2021-03-05 브리스톨-마이어스 스큅 컴퍼니 T 세포 활성화제로서 유용한 나프티리디논 화합물
WO2020005003A1 (ko) * 2018-06-29 2020-01-02 주식회사 와이바이오로직스 Lag-3에 특이적으로 결합하는 단클론항체 및 이의 용도
CA3105448A1 (en) 2018-07-03 2020-01-09 Elstar Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
WO2020010177A1 (en) 2018-07-06 2020-01-09 Kymera Therapeutics, Inc. Tricyclic crbn ligands and uses thereof
BR112020027095A2 (pt) 2018-07-09 2021-03-30 Five Prime Therapeutics, Inc. Anticorpos de ligação a ilt4
SG11202011872QA (en) 2018-07-10 2021-01-28 Novartis Ag 3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and their use in the treatment of ikaros family zinc finger 2 (ikzf2)-dependent diseases
AR116109A1 (es) 2018-07-10 2021-03-31 Novartis Ag Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
KR20210031722A (ko) 2018-07-11 2021-03-22 파이브 프라임 테라퓨틱스, 인크. 산성 pH에서 VISTA에 결합하는 항체
WO2020018503A2 (en) 2018-07-16 2020-01-23 Regeneron Pharmaceuticals, Inc. Anti-il36r antibodies
JP7072715B2 (ja) 2018-07-20 2022-05-20 サーフィス オンコロジー インコーポレイテッド 抗ｃｄ１１２ｒ組成物及び方法
US20210355113A1 (en) 2018-07-23 2021-11-18 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
WO2020023355A1 (en) 2018-07-23 2020-01-30 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
WO2020021465A1 (en) 2018-07-25 2020-01-30 Advanced Accelerator Applications (Italy) S.R.L. Method of treatment of neuroendocrine tumors
AU2019309849A1 (en) 2018-07-26 2021-03-18 Bristol-Myers Squibb Company LAG-3 combination therapy for the treatment of cancer
JP7177543B2 (ja) * 2018-08-21 2022-11-24 エービーエル バイオ インコーポレイテッド 抗ｐｄ－ｌ１／抗ｌａｇ３二重特異性抗体およびその使用
US11253525B2 (en) 2018-08-29 2022-02-22 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
US10959986B2 (en) 2018-08-29 2021-03-30 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
CN113164419A (zh) 2018-09-07 2021-07-23 皮克医疗公司 Eif4e抑制剂和其用途
AU2019339777B2 (en) 2018-09-12 2022-09-01 Novartis Ag Antiviral pyridopyrazinedione compounds
JP2022501009A (ja) 2018-09-21 2022-01-06 イノベント バイオロジックス （スウツォウ） カンパニー，リミテッド 新規インターロイキン２およびその使用
JP2022500002A (ja) 2018-09-21 2022-01-04 イノベント バイオロジックス （スウツォウ） カンパニー，リミテッド 新規インターロイキン２およびその使用
IL281683B2 (en) 2018-09-25 2023-04-01 Harpoon Therapeutics Inc dll3 binding proteins and methods of use
CN113164777A (zh) 2018-09-27 2021-07-23 马伦戈治疗公司 Csf1r/ccr2多特异性抗体
EP3856779A1 (en) 2018-09-28 2021-08-04 Novartis AG Cd22 chimeric antigen receptor (car) therapies
WO2020069409A1 (en) 2018-09-28 2020-04-02 Novartis Ag Cd19 chimeric antigen receptor (car) and cd22 car combination therapies
BR112021005606A2 (pt) 2018-09-29 2021-06-22 Novartis Ag processo de produção de um composto para inibir a atividade de shp2
CN113195523A (zh) 2018-10-03 2021-07-30 Xencor股份有限公司 IL-12异源二聚体Fc融合蛋白
WO2020076969A2 (en) 2018-10-10 2020-04-16 Tilos Therapeutics, Inc. Anti-lap antibody variants and uses thereof
MA53862A (fr) 2018-10-12 2022-01-19 Xencor Inc Protéines de fusion fc d'il-15/il-15ralpha ciblant pd-1 et utilisations dans des polythérapies faisant intervenir celles-ci
US20210338813A1 (en) 2018-10-19 2021-11-04 Bristol-Myers Squibb Company Combination Therapy for Melanoma
EP3873534A1 (en) 2018-10-29 2021-09-08 Mersana Therapeutics, Inc. Cysteine engineered antibody-drug conjugates with peptide-containing linkers
WO2020089811A1 (en) 2018-10-31 2020-05-07 Novartis Ag Dc-sign antibody drug conjugates
CN113614108A (zh) 2018-11-01 2021-11-05 朱诺治疗学股份有限公司 G蛋白偶合受体c类5族成员d(gprc5d)特异性嵌合抗原受体
US20210393690A1 (en) 2018-11-01 2021-12-23 Juno Therapeutics, Inc. Methods for treatment using chimeric antigen receptors specific for b-cell maturation antigen
JP2022509942A (ja) 2018-11-16 2022-01-25 ブリストル－マイヤーズ スクイブ カンパニー 抗ｎｋｇ２ａ抗体およびその使用
WO2020102770A1 (en) 2018-11-16 2020-05-22 Juno Therapeutics, Inc. Methods of dosing engineered t cells for the treatment of b cell malignancies
CN113423427A (zh) 2018-11-30 2021-09-21 凯麦拉医疗公司 Irak降解剂和其用途
KR20210117260A (ko) 2018-11-30 2021-09-28 주노 쎄러퓨티크스 인코퍼레이티드 입양 세포 요법을 사용한 치료방법
US11034710B2 (en) 2018-12-04 2021-06-15 Sumitomo Dainippon Pharma Oncology, Inc. CDK9 inhibitors and polymorphs thereof for use as agents for treatment of cancer
EP3670659A1 (en) 2018-12-20 2020-06-24 Abivax Biomarkers, and uses in treatment of viral infections, inflammations, or cancer
WO2020132646A1 (en) 2018-12-20 2020-06-25 Xencor, Inc. Targeted heterodimeric fc fusion proteins containing il-15/il-15ra and nkg2d antigen binding domains
MX2021007392A (es) 2018-12-20 2021-08-24 Novartis Ag Regimen de dosificacion y combinacion farmaceutica que comprende derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona.
JP7450622B2 (ja) 2018-12-21 2024-03-15 ヴァレリオ・セラピューティクス 新規のコンジュゲートされた核酸分子及びその使用
WO2020128637A1 (en) 2018-12-21 2020-06-25 Novartis Ag Use of il-1 binding antibodies in the treatment of a msi-h cancer
WO2020128613A1 (en) 2018-12-21 2020-06-25 Novartis Ag Use of il-1beta binding antibodies
WO2020128620A1 (en) 2018-12-21 2020-06-25 Novartis Ag Use of il-1beta binding antibodies
CN113614109A (zh) 2018-12-21 2021-11-05 Ose免疫疗法公司 双功能抗pd-1/il-7分子
KR20210107730A (ko) 2018-12-21 2021-09-01 노파르티스 아게 골수 형성이상 증후군의 치료 또는 예방에서의 il-1 베타 항체의 용도
US11235032B2 (en) 2019-01-23 2022-02-01 Massachusetts Institute Of Technology Combination immunotherapy dosing regimen for immune checkpoint blockade
US20220096651A1 (en) 2019-01-29 2022-03-31 Juno Therapeutics, Inc. Antibodies and chimeric antigen receptors specific for receptor tyrosine kinase like orphan receptor 1 (ror1)
CA3127502A1 (en) 2019-02-12 2020-08-20 Sumitomo Dainippon Pharma Oncology, Inc. Formulations comprising heterocyclic protein kinase inhibitors
WO2020165374A1 (en) 2019-02-14 2020-08-20 Ose Immunotherapeutics Bifunctional molecule comprising il-15ra
MX2021009763A (es) 2019-02-15 2021-09-08 Novartis Ag Derivados de 3-(1-oxo-5-(piperidin-4-il)isoindolin-2-il)piperidina -2,6-diona y usos de los mismos.
EP3924055B1 (en) 2019-02-15 2024-04-03 Novartis AG Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
CN111620949A (zh) * 2019-02-28 2020-09-04 三生国健药业（上海）股份有限公司 结合人lag-3的抗体、其制备方法和用途
WO2020187998A1 (en) 2019-03-19 2020-09-24 Fundació Privada Institut D'investigació Oncològica De Vall Hebron Combination therapy with omomyc and an antibody binding pd-1 or ctla-4 for the treatment of cancer
JP2022525149A (ja) 2019-03-20 2022-05-11 スミトモ ダイニッポン ファーマ オンコロジー， インコーポレイテッド ベネトクラクスが失敗した急性骨髄性白血病（ａｍｌ）の処置
US11712433B2 (en) 2019-03-22 2023-08-01 Sumitomo Pharma Oncology, Inc. Compositions comprising PKM2 modulators and methods of treatment using the same
KR20220009941A (ko) 2019-03-26 2022-01-25 더 리젠츠 오브 더 유니버시티 오브 미시간 Stat3의 저분자 분해제
US20220185831A1 (en) 2019-03-29 2022-06-16 The Regents Of The University Of Michigan Stat3 protein degraders
EP3946462A1 (en) 2019-04-02 2022-02-09 BicycleTX Limited Bicycle toxin conjugates and uses thereof
SG11202110829YA (en) 2019-04-05 2021-10-28 Kymera Therapeutics Inc Stat degraders and uses thereof
EP3725370A1 (en) 2019-04-19 2020-10-21 ImmunoBrain Checkpoint, Inc. Modified anti-pd-l1 antibodies and methods and uses for treating a neurodegenerative disease
GB201906118D0 (en) 2019-05-01 2019-06-12 Immutep S A Anti-LAG-3 binding molecules
US20230242478A1 (en) 2019-05-13 2023-08-03 Bristol-Myers Squibb Company AGONISTS OF ROR GAMMAt
CN113825527A (zh) 2019-05-13 2021-12-21 瑞泽恩制药公司 用于在治疗癌症中增强效力的pd-1抑制剂和lag-3抑制剂的组合
WO2020231766A1 (en) 2019-05-13 2020-11-19 Bristol-Myers Squibb Company AGONISTS OF ROR GAMMAt
CN114174538A (zh) 2019-05-30 2022-03-11 百时美施贵宝公司 适合于免疫肿瘤学疗法的多肿瘤基因特征
EP3976832A1 (en) 2019-05-30 2022-04-06 Bristol-Myers Squibb Company Methods of identifying a subject suitable for an immuno-oncology (i-o) therapy
CN110320367A (zh) * 2019-05-30 2019-10-11 广州医科大学附属第一医院（广州呼吸中心） 基于lag-3的诊断试剂盒及其在帕金森病诊断产品上的应用
US20220233691A1 (en) 2019-05-30 2022-07-28 Bristol-Myers Squibb Company Cell localization signature and combination therapy
SG11202113154YA (en) 2019-05-31 2021-12-30 Ikena Oncology Inc Tead inhibitors and uses thereof
JP2022536898A (ja) 2019-06-12 2022-08-22 アスクジーン・ファーマ・インコーポレイテッド 新規ｉｌ－１５プロドラッグおよびその使用方法
JP2022536728A (ja) 2019-06-12 2022-08-18 ヴァンダービルト ユニバーシティー アミノ酸輸送阻害剤としてのジベンジルアミン類
EP3983084A1 (en) 2019-06-12 2022-04-20 Vanderbilt University Amino acid transport inhibitors and the uses thereof
JP2022538974A (ja) 2019-06-26 2022-09-07 マサチューセッツ インスチテュート オブ テクノロジー 免疫調節融合タンパク質－金属水酸化物錯体およびその方法
US11529350B2 (en) 2019-07-03 2022-12-20 Sumitomo Pharma Oncology, Inc. Tyrosine kinase non-receptor 1 (TNK1) inhibitors and uses thereof
IT201900011676A1 (it) 2019-07-12 2021-01-12 St Superiore Di Sanita Anticorpo ricombinante umano contro il recettore di membrana LAG3, suoi usi medici e diagnostici.
EP3999510A1 (en) 2019-07-16 2022-05-25 The Regents Of The University Of Michigan Imidazopyrimidines as eed inhibitors and the use thereof
WO2021024020A1 (en) 2019-08-06 2021-02-11 Astellas Pharma Inc. Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer
WO2021026179A1 (en) 2019-08-06 2021-02-11 Bristol-Myers Squibb Company AGONISTS OF ROR GAMMAt
JP2022545735A (ja) 2019-08-27 2022-10-28 ザ リージェンツ オブ ザ ユニヴァシティ オブ ミシガン セレブロンｅ３リガーゼ阻害剤
AR119821A1 (es) 2019-08-28 2022-01-12 Bristol Myers Squibb Co Compuestos de piridopirimidinonilo sustituidos útiles como activadores de células t
MX2022002877A (es) 2019-09-13 2022-08-08 Nimbus Saturn Inc Antagonistas de cinasa progenitora hematopoyetica 1 (hpk1) y sus usos.
US20220348651A1 (en) 2019-09-18 2022-11-03 Novartis Ag Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
JP2022548775A (ja) 2019-09-19 2022-11-21 ザ リージェンツ オブ ザ ユニヴァシティ オブ ミシガン スピロ環式アンドロゲン受容体タンパク質分解剤
MX2022003204A (es) 2019-09-19 2022-04-18 Bristol Myers Squibb Co Anticuerpos de union al supresor de activacion de linfocitos t que contiene inmunoglobulina con dominio v (vista) a ph acido.
US20220348653A1 (en) 2019-09-22 2022-11-03 Bristol-Myers Squibb Company Quantitative Spatial Profiling for LAG-3 Antagonist Therapy
AU2020353055B2 (en) 2019-09-26 2024-03-07 Gilead Sciences, Inc. Antiviral pyrazolopyridinone compounds
US11851466B2 (en) 2019-10-03 2023-12-26 Xencor, Inc. Targeted IL-12 heterodimeric Fc-fusion proteins
TW202128757A (zh) 2019-10-11 2021-08-01 美商建南德克公司 具有改善之特性的 PD-1 標靶 IL-15/IL-15Rα FC 融合蛋白
EP4048281A1 (en) 2019-10-21 2022-08-31 Novartis AG Combination therapies with venetoclax and tim-3 inhibitors
JP2022553306A (ja) 2019-10-21 2022-12-22 ノバルティス アーゲー Ｔｉｍ－３阻害剤およびその使用
US11459389B2 (en) 2019-10-24 2022-10-04 Massachusetts Institute Of Technology Monoclonal antibodies that bind human CD161
WO2021079958A1 (ja) * 2019-10-25 2021-04-29 第一三共株式会社 抗ｇａｒｐ抗体と免疫調節剤の組み合わせ
JP2023500506A (ja) 2019-11-04 2023-01-06 アストラゼネカ・アクチエボラーグ 癌を治療するための組み合わせ療法
WO2021092221A1 (en) 2019-11-06 2021-05-14 Bristol-Myers Squibb Company Methods of identifying a subject with a tumor suitable for a checkpoint inhibitor therapy
WO2021092220A1 (en) 2019-11-06 2021-05-14 Bristol-Myers Squibb Company Methods of identifying a subject with a tumor suitable for a checkpoint inhibitor therapy
KR20220093349A (ko) * 2019-11-08 2022-07-05 브리스톨-마이어스 스큅 컴퍼니 흑색종에 대한 lag-3 길항제 요법
AU2020387392A1 (en) 2019-11-19 2022-07-14 Bristol-Myers Squibb Company Compounds useful as inhibitors of Helios protein
AU2020394424A1 (en) 2019-11-26 2022-06-16 Ikena Oncology, Inc. Polymorphic carbazole derivatives and uses thereof
WO2021108613A1 (en) 2019-11-26 2021-06-03 Novartis Ag Cd19 and cd22 chimeric antigen receptors and uses thereof
IL293357A (en) 2019-11-26 2022-07-01 Bristol Myers Squibb Co Salts/crystals of (r)-n-(4-chlorophenyl)-2-((1s,4s)-4-(6-fluoroquinolin-4-yl)cyclohexyl)propanamide
WO2021113644A1 (en) 2019-12-05 2021-06-10 Multivir Inc. Combinations comprising a cd8+ t cell enhancer, an immune checkpoint inhibitor and radiotherapy for targeted and abscopal effects for the treatment of cancer
WO2021127190A1 (en) 2019-12-17 2021-06-24 Kymera Therapeutics, Inc. Irak degraders and uses thereof
EP4076524A4 (en) 2019-12-17 2023-11-29 Kymera Therapeutics, Inc. IRAQ DEGRADERS AND USES THEREOF
WO2021122866A1 (en) 2019-12-17 2021-06-24 Ose Immunotherapeutics Bifunctional molecules comprising an il-7 variant
US20230333090A1 (en) * 2019-12-20 2023-10-19 Merck Sharp & Dohme Llc Lag3 antagonist cell based potency assay
AU2020406350A1 (en) 2019-12-20 2022-08-11 Novartis Ag Uses of anti-TGF-beta antibodies and checkpoint inhibitors for the treatment of proliferative diseases
WO2021133920A1 (en) 2019-12-23 2021-07-01 Kymera Therapeutics, Inc. Smarca degraders and uses thereof
CN115175907A (zh) 2019-12-23 2022-10-11 百时美施贵宝公司 可用作t细胞激活剂的经取代的哌嗪衍生物
AU2020414688A1 (en) 2019-12-23 2022-08-18 Bristol-Myers Squibb Company Substituted quinolinonyl piperazine compounds useful as T cell activators
AU2020412472A1 (en) 2019-12-23 2022-08-18 Bristol-Myers Squibb Company Substituted heteroaryl compounds useful as T cell activators
AR120823A1 (es) 2019-12-23 2022-03-23 Bristol Myers Squibb Co Compuestos bicíclicos sustituidos útiles como activadores de células t
KR20220119454A (ko) 2019-12-23 2022-08-29 브리스톨-마이어스 스큅 컴퍼니 T 세포 활성화제로서 유용한 치환된 퀴나졸리닐 화합물
WO2021138407A2 (en) 2020-01-03 2021-07-08 Marengo Therapeutics, Inc. Multifunctional molecules that bind to cd33 and uses thereof
CA3166898A1 (en) 2020-01-06 2021-07-15 Hifibio (Hk) Limited Anti-tnfr2 antibody and uses thereof
TW202140473A (zh) 2020-01-15 2021-11-01 美商纜圖藥品公司 Map4k1抑制劑
US20230058489A1 (en) 2020-01-17 2023-02-23 Novartis Ag Combination comprising a tim-3 inhibitor and a hypomethylating agent for use in treating myelodysplastic syndrome or chronic myelomonocytic leukemia
US20230087600A1 (en) 2020-02-06 2023-03-23 Bristol-Myers Squibb Company Il-10 and uses thereof
TW202146452A (zh) 2020-02-28 2021-12-16 瑞士商諾華公司 結合ｃｄ１２３和ｃｄ３之雙特異性抗體的給藥
EP4114529A1 (en) 2020-03-03 2023-01-11 PIC Therapeutics, Inc. Eif4e inhibitors and uses thereof
WO2021183428A1 (en) 2020-03-09 2021-09-16 Bristol-Myers Squibb Company Antibodies to cd40 with enhanced agonist activity
BR112022018678A2 (pt) 2020-03-19 2022-11-01 Kymera Therapeutics Inc Degradadores de mdm2 e usos dos mesmos
CA3173831A1 (en) 2020-03-19 2021-09-23 Arcus Biosciences, Inc. Tetralin and tetrahydroquinoline compounds as inhibitors of hif-2alpha
TW202140441A (zh) 2020-03-23 2021-11-01 美商必治妥美雅史谷比公司 經取代之側氧基異吲哚啉化合物
WO2021195481A1 (en) 2020-03-26 2021-09-30 The Regents Of The University Of Michigan Small molecule stat protein degraders
WO2021207449A1 (en) 2020-04-09 2021-10-14 Merck Sharp & Dohme Corp. Affinity matured anti-lap antibodies and uses thereof
IL297147A (en) 2020-04-10 2022-12-01 Juno Therapeutics Inc Methods and Uses Related to Transgenic Cell Therapy with a Chimeric Antigen Receptor Directed to a B-Cell Maturation Antigen
WO2021231732A1 (en) 2020-05-15 2021-11-18 Bristol-Myers Squibb Company Antibodies to garp
US11667711B2 (en) 2020-05-27 2023-06-06 Agilent Technologies, Inc. Anti-human LAG-3 antibodies and their use in immunohistochemistry (IHC)
WO2021247591A1 (en) 2020-06-02 2021-12-09 Arcus Biosciences, Inc. Antibodies to tigit
JP2023528071A (ja) 2020-06-03 2023-07-03 エムヴィ バイオセラピューティクス エスエー Ａｔｐ加水分解酵素と免疫チェックポイントモジュレーターとの組合せ、並びにその使用
TW202210483A (zh) 2020-06-03 2022-03-16 美商凱麥拉醫療公司 Irak降解劑之結晶型
CN111808192B (zh) * 2020-06-05 2022-02-15 北京天广实生物技术股份有限公司 结合lag3的抗体及其用途
TW202214857A (zh) 2020-06-19 2022-04-16 法商昂席歐公司 新型結合核酸分子及其用途
WO2021258010A1 (en) 2020-06-19 2021-12-23 Gossamer Bio Services, Inc. Oxime compounds useful as t cell activators
JP2023531676A (ja) 2020-06-23 2023-07-25 ノバルティス アーゲー ３－（１－オキソイソインドリン－２－イル）ピぺリジン－２，６－ジオン誘導体を含む投与レジメン
IL298993A (en) 2020-07-07 2023-02-01 BioNTech SE Therapeutic RNA for HPV positive cancer
WO2022011204A1 (en) 2020-07-10 2022-01-13 The Regents Of The University Of Michigan Small molecule androgen receptor protein degraders
WO2022011205A1 (en) 2020-07-10 2022-01-13 The Regents Of The University Of Michigan Androgen receptor protein degraders
JP2023536462A (ja) 2020-07-30 2023-08-25 カイメラ セラピューティクス， インコーポレイテッド 変異体リンパ腫を処置する方法
CN116134027A (zh) 2020-08-03 2023-05-16 诺华股份有限公司 杂芳基取代的3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物及其用途
KR20230077722A (ko) 2020-08-10 2023-06-01 지브이20 테라퓨틱스 엘엘씨 Igsf8을 표적화하여 자가면역 질환 및 암을 치료하기 위한 조성물 및 방법
WO2022036079A1 (en) 2020-08-13 2022-02-17 Bristol-Myers Squibb Company Methods of redirecting of il-2 to target cells of interest
CA3186504A1 (en) 2020-08-17 2022-02-24 Stephen J. Blakemore Bicycle conjugates specific for nectin-4 and uses thereof
EP4204458A1 (en) 2020-08-26 2023-07-05 Marengo Therapeutics, Inc. Methods of detecting trbc1 or trbc2
IL300813A (en) 2020-08-28 2023-04-01 Bristol Myers Squibb Co LAG-3 antagonist therapy for hepatocellular carcinoma
EP4204021A1 (en) 2020-08-31 2023-07-05 Advanced Accelerator Applications International S.A. Method of treating psma-expressing cancers
MX2023002326A (es) 2020-08-31 2023-03-21 Bristol Myers Squibb Co Firma de localizacion celular e inmunoterapia.
WO2022043558A1 (en) 2020-08-31 2022-03-03 Advanced Accelerator Applications International Sa Method of treating psma-expressing cancers
CN116348137A (zh) 2020-09-14 2023-06-27 勃林格殷格翰国际有限公司 异源初免加强疫苗
AU2021357841A1 (en) 2020-10-08 2023-06-15 Affimed Gmbh Trispecific binders
CA3198456A1 (en) 2020-10-14 2022-04-21 Five Prime Therapeutics, Inc. Anti-c-c chemokine receptor 8 (ccr8) antibodies and methods of use thereof
CA3196496A1 (en) 2020-10-23 2022-04-28 Laurence David TOMS Lag-3 antagonist therapy for lung cancer
WO2022097060A1 (en) 2020-11-06 2022-05-12 Novartis Ag Cd19 binding molecules and uses thereof
WO2022112198A1 (en) 2020-11-24 2022-06-02 Worldwide Innovative Network Method to select the optimal immune checkpoint therapies
JP2024508207A (ja) 2020-12-02 2024-02-26 ブイアイビー ブイゼットダブリュ がんに対する組み合わせ治療におけるｌｔｂｒアゴニスト
EP4255895A1 (en) 2020-12-02 2023-10-11 Ikena Oncology, Inc. Tead inhibitors and uses thereof
WO2022120353A1 (en) 2020-12-02 2022-06-09 Ikena Oncology, Inc. Tead inhibitors and uses thereof
WO2022120179A1 (en) 2020-12-03 2022-06-09 Bristol-Myers Squibb Company Multi-tumor gene signatures and uses thereof
US20240050432A1 (en) 2020-12-08 2024-02-15 Infinity Pharmaceuticals, Inc. Eganelisib for use in the treatment of pd-l1 negative cancer
TW202237119A (zh) 2020-12-10 2022-10-01 美商住友製藥腫瘤公司 Ａｌｋ﹘５抑制劑和彼之用途
CN114621344B (zh) * 2020-12-10 2022-08-30 北京东方百泰生物科技股份有限公司 一种抗lag-3单克隆抗体的纯化方法
WO2022133083A1 (en) 2020-12-16 2022-06-23 Gossamer Bio Services, Inc. Compounds useful as t cell activators
WO2022135666A1 (en) 2020-12-21 2022-06-30 BioNTech SE Treatment schedule for cytokine proteins
TW202245808A (zh) 2020-12-21 2022-12-01 德商拜恩迪克公司 用於治療癌症之治療性ｒｎａ
WO2022135667A1 (en) 2020-12-21 2022-06-30 BioNTech SE Therapeutic rna for treating cancer
EP4267172A1 (en) 2020-12-28 2023-11-01 Bristol-Myers Squibb Company Subcutaneous administration of pd1/pd-l1 antibodies
WO2022146947A1 (en) 2020-12-28 2022-07-07 Bristol-Myers Squibb Company Antibody compositions and methods of use thereof
WO2022148781A1 (en) 2021-01-05 2022-07-14 Institut Curie Combination of mcoln activators and immune checkpoint inhibitors
WO2022148979A1 (en) 2021-01-11 2022-07-14 Bicycletx Limited Methods for treating cancer
JP2024506858A (ja) 2021-02-02 2024-02-15 リミナル・バイオサイエンシーズ・リミテッド Ｇｐｒ８４アンタゴニストおよびその使用
CA3206501A1 (en) 2021-02-02 2022-08-11 Shaun Abbott Gpr84 antagonists and uses thereof
AU2022218137A1 (en) 2021-02-03 2023-08-24 Mozart Therapeutics, Inc. Binding agents and methods of using the same
WO2022169921A1 (en) 2021-02-04 2022-08-11 Bristol-Myers Squibb Company Benzofuran compounds as sting agonists
PE20231505A1 (es) 2021-02-12 2023-09-26 Hoffmann La Roche Derivados de tetrahidroazepina biciclicos para el tratamiento del cancer
WO2022174269A1 (en) 2021-02-15 2022-08-18 Kymera Therapeutics, Inc. Irak4 degraders and uses thereof
US20220275090A1 (en) 2021-02-22 2022-09-01 Janssen Biotech, Inc. Combination Therapies with Anti-CD38 Antibodies and PARP or Adenosine Receptor Inhibitors
WO2022187423A1 (en) 2021-03-03 2022-09-09 The Regents Of The University Of Michigan Cereblon ligands
WO2022187419A1 (en) 2021-03-03 2022-09-09 The Regents Of The University Of Michigan Small molecule degraders of androgen receptor
CN117295737A (zh) 2021-03-05 2023-12-26 林伯士萨顿公司 Hpk1拮抗剂和其用途
WO2022192145A1 (en) 2021-03-08 2022-09-15 Blueprint Medicines Corporation Map4k1 inhibitors
US11918582B2 (en) 2021-03-15 2024-03-05 Rapt Therapeutics, Inc. Pyrazole pyrimidine compounds and uses thereof
AU2022246593A1 (en) 2021-03-29 2023-10-12 Juno Therapeutics, Inc. Methods for dosing and treatment with a combination of a checkpoint inhibitor therapy and a car t cell therapy
EP4314068A1 (en) 2021-04-02 2024-02-07 The Regents Of The University Of California Antibodies against cleaved cdcp1 and uses thereof
BR112023020410A2 (pt) 2021-04-05 2023-11-28 Bristol Myers Squibb Co Compostos de oxoisoindolina substituída por piridinila para tratamento de câncer
BR112023020077A2 (pt) 2021-04-06 2023-11-14 Bristol Myers Squibb Co Compostos de oxoisoindolina substituída por piridinila
TW202304979A (zh) 2021-04-07 2023-02-01 瑞士商諾華公司 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
CA3214757A1 (en) 2021-04-08 2022-10-13 Andreas Loew Multifuntional molecules binding to tcr and uses thereof
AU2022253351A1 (en) 2021-04-09 2023-10-12 Ose Immunotherapeutics New scaffold for bifunctional molecules with improved properties
EP4320156A1 (en) 2021-04-09 2024-02-14 Ose Immunotherapeutics Scaffold for bifunctioanl molecules comprising pd-1 or cd28 and sirp binding domains
JP2024516371A (ja) 2021-04-13 2024-04-15 ヌバレント， インク． Ｅｇｆｒ変異を有するがんを処置するためのアミノ置換ヘテロ環類
EP4323066A1 (en) 2021-04-16 2024-02-21 Ikena Oncology, Inc. Mek inhibitors and uses thereof
EP4337694A1 (en) 2021-05-12 2024-03-20 Dana-Farber Cancer Institute, Inc. Lag3 and gal3 inhibitory agents, xbp1, cs1, and cd138 peptides, and methods of use thereof
AR125874A1 (es) 2021-05-18 2023-08-23 Novartis Ag Terapias de combinación
CN117295741A (zh) 2021-05-21 2023-12-26 艾库斯生物科学有限公司 Axl化合物
TW202313603A (zh) 2021-05-21 2023-04-01 美商阿克思生物科學有限公司 Axl抑制劑化合物
AU2022281461A1 (en) 2021-05-25 2024-01-04 Edelweiss Immune Inc C-x-c motif chemokine receptor 6 (cxcr6) binding molecules, and methods of using the same
TW202307210A (zh) 2021-06-01 2023-02-16 瑞士商諾華公司 Ｃｄ１９和ｃｄ２２嵌合抗原受體及其用途
AU2022312698A1 (en) 2021-07-13 2024-01-25 BioNTech SE Multispecific binding agents against cd40 and cd137 in combination therapy for cancer
AR126442A1 (es) 2021-07-14 2023-10-11 Blueprint Medicines Corp Inhibidores de map4k1
WO2023288264A1 (en) 2021-07-15 2023-01-19 Blueprint Medicines Corporation Map4k1 inhibitors
IL308154A (en) 2021-07-30 2023-12-01 Affimed Gmbh Double structure antibodies
IL310924A (en) 2021-08-25 2024-04-01 Pic Therapeutics Inc EIF4E inhibitors and their uses
US20230134932A1 (en) 2021-08-25 2023-05-04 PIC Therapeutics, Inc. Eif4e inhibitors and uses thereof
TW202328090A (zh) 2021-09-08 2023-07-16 美商雷度納製藥公司 Ｐａｐｄ５及／或ｐａｐｄ７抑制劑
TW202333802A (zh) 2021-10-11 2023-09-01 德商拜恩迪克公司 用於肺癌之治療性rna(二)
WO2023076876A1 (en) 2021-10-26 2023-05-04 Mozart Therapeutics, Inc. Modulation of immune responses to viral vectors
US20230159466A1 (en) 2021-10-29 2023-05-25 Arcus Biosciences, Inc. Inhibitors of hif-2alpha and methods of use thereof
CA3224890A1 (en) 2021-10-29 2023-05-04 Bristol-Myers Squibb Company Lag-3 antagonist therapy for hematological cancer
US20230136301A1 (en) 2021-11-03 2023-05-04 Janssen Biotech, Inc. Corticosteriod Reduction in Treatment with Anti-CD38 Antibody
WO2023111203A1 (en) 2021-12-16 2023-06-22 Onxeo New conjugated nucleic acid molecules and their uses
WO2023114984A1 (en) 2021-12-17 2023-06-22 Ikena Oncology, Inc. Tead inhibitors and uses thereof
WO2023122772A1 (en) 2021-12-22 2023-06-29 Gossamer Bio Services, Inc. Oxime derivatives useful as t cell activators
WO2023122777A1 (en) 2021-12-22 2023-06-29 Gossamer Bio Services, Inc. Oxime derivatives useful as t cell activators
WO2023122778A1 (en) 2021-12-22 2023-06-29 Gossamer Bio Services, Inc. Pyridazinone derivatives useful as t cell activators
WO2023147371A1 (en) 2022-01-26 2023-08-03 Bristol-Myers Squibb Company Combination therapy for hepatocellular carcinoma
WO2023150186A1 (en) 2022-02-01 2023-08-10 Arvinas Operations, Inc. Dgk targeting compounds and uses thereof
TW202342474A (zh) 2022-02-14 2023-11-01 美商基利科學股份有限公司 抗病毒吡唑并吡啶酮化合物
WO2023164638A1 (en) 2022-02-25 2023-08-31 Bristol-Myers Squibb Company Combination therapy for colorectal carcinoma
WO2023168404A1 (en) 2022-03-04 2023-09-07 Bristol-Myers Squibb Company Methods of treating a tumor
WO2023170606A1 (en) 2022-03-08 2023-09-14 Alentis Therapeutics Ag Use of anti-claudin-1 antibodies to increase t cell availability
WO2023173057A1 (en) 2022-03-10 2023-09-14 Ikena Oncology, Inc. Mek inhibitors and uses thereof
WO2023173053A1 (en) 2022-03-10 2023-09-14 Ikena Oncology, Inc. Mek inhibitors and uses thereof
WO2023178192A1 (en) 2022-03-15 2023-09-21 Compugen Ltd. Il-18bp antagonist antibodies and their use in monotherapy and combination therapy in the treatment of cancer
WO2023178201A2 (en) * 2022-03-15 2023-09-21 The Board Of Trustees Of The Leland Stanford Junior University Methods of identifying anti-lag-3 agents
WO2023178329A1 (en) 2022-03-18 2023-09-21 Bristol-Myers Squibb Company Methods of isolating polypeptides
WO2023211889A1 (en) 2022-04-25 2023-11-02 Ikena Oncology, Inc. Polymorphic compounds and uses thereof
WO2023214325A1 (en) 2022-05-05 2023-11-09 Novartis Ag Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors
WO2023230205A1 (en) 2022-05-25 2023-11-30 Ikena Oncology, Inc. Mek inhibitors and uses thereof
WO2023235847A1 (en) 2022-06-02 2023-12-07 Bristol-Myers Squibb Company Antibody compositions and methods of use thereof
WO2023250400A1 (en) 2022-06-22 2023-12-28 Juno Therapeutics, Inc. Treatment methods for second line therapy of cd19-targeted car t cells
WO2024003360A1 (en) 2022-07-01 2024-01-04 Institut Curie Biomarkers and uses thereof for the treatment of neuroblastoma
WO2024015251A1 (en) 2022-07-15 2024-01-18 Arcus Biosciences, Inc. Inhibitors of hpk1 and methods of use thereof
WO2024020034A1 (en) 2022-07-20 2024-01-25 Arcus Biosciences, Inc. Cbl-b inhibitors and methods of use thereof
WO2024028386A1 (en) 2022-08-02 2024-02-08 Ose Immunotherapeutics Multifunctional molecule directed against cd28
WO2024028363A1 (en) 2022-08-02 2024-02-08 Liminal Biosciences Limited Heteroaryl carboxamide and related gpr84 antagonists and uses thereof
WO2024028364A1 (en) 2022-08-02 2024-02-08 Liminal Biosciences Limited Aryl-triazolyl and related gpr84 antagonists and uses thereof
WO2024028365A1 (en) 2022-08-02 2024-02-08 Liminal Biosciences Limited Substituted pyridone gpr84 antagonists and uses thereof
WO2024031091A2 (en) 2022-08-05 2024-02-08 Juno Therapeutics, Inc. Chimeric antigen receptors specific for gprc5d and bcma
WO2024036100A1 (en) 2022-08-08 2024-02-15 Bristol-Myers Squibb Company Substituted tetrazolyl compounds useful as t cell activators
WO2024036101A1 (en) 2022-08-09 2024-02-15 Bristol-Myers Squibb Company Tertiary amine substituted bicyclic compounds useful as t cell activators
WO2024033389A1 (en) 2022-08-11 2024-02-15 F. Hoffmann-La Roche Ag Bicyclic tetrahydrothiazepine derivatives
WO2024033388A1 (en) 2022-08-11 2024-02-15 F. Hoffmann-La Roche Ag Bicyclic tetrahydrothiazepine derivatives
WO2024033458A1 (en) 2022-08-11 2024-02-15 F. Hoffmann-La Roche Ag Bicyclic tetrahydroazepine derivatives
WO2024033457A1 (en) 2022-08-11 2024-02-15 F. Hoffmann-La Roche Ag Bicyclic tetrahydrothiazepine derivatives
WO2024040195A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
WO2024059142A1 (en) 2022-09-14 2024-03-21 Arcus Biosciences, Inc. Dispersions of etrumadenant
WO2024081385A1 (en) 2022-10-14 2024-04-18 Arcus Biosciences, Inc. Hpk1 inhibitors and methods of use thereof

Family Cites Families (152)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US153043A (en) 1874-07-14 Improvement in middlings-separators
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
DE3572982D1 (en) 1984-03-06 1989-10-19 Takeda Chemical Industries Ltd Chemically modified lymphokine and production thereof
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US5374548A (en) 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
MX9203291A (es) 1985-06-26 1992-08-01 Liposome Co Inc Metodo para acoplamiento de liposomas.
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
AU600575B2 (en) 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
US5476996A (en) 1988-06-14 1995-12-19 Lidak Pharmaceuticals Human immune system in non-human animal
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
ATE135370T1 (de) 1988-12-22 1996-03-15 Kirin Amgen Inc Chemisch modifizierte granulocytenkolonie erregender faktor
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5976877A (en) * 1990-01-08 1999-11-02 Institut National De La Sante Et De La Recherche Medicale (Inserm) Proteins produced by human lymphocytes DNA sequence encoding these proteins and their pharmaceutical and biological uses
FR2656800B1 (fr) * 1990-01-08 1992-05-15 Roussy Inst Gustave Nouvelles proteines produits par les lymphocytes humains, sequence d'adn codant pour ces proteines et applications pharmaceutiques et biologiques.
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
JP3068180B2 (ja) 1990-01-12 2000-07-24 アブジェニックス インコーポレイテッド 異種抗体の生成
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
ATE158021T1 (de) 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
GB9108652D0 (en) 1991-04-23 1991-06-12 Antisoma Ltd Immunoreactive compounds
US5885793A (en) 1991-12-02 1999-03-23 Medical Research Council Production of anti-self antibodies from antibody segment repertoires and displayed on phage
CA2124967C (en) 1991-12-17 2008-04-08 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
EP0640094A1 (en) 1992-04-24 1995-03-01 The Board Of Regents, The University Of Texas System Recombinant production of immunoglobulin-like domains in prokaryotic cells
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
WO1994006448A1 (en) 1992-09-16 1994-03-31 The Scripps Research Institute Human neutralizing monoclonal antibodies to respiratory syncytial virus
JP3919830B2 (ja) 1992-11-28 2007-05-30 財団法人化学及血清療法研究所 抗ネコヘルペスウイルス−１組換え抗体および該抗体をコードする遺伝子断片
AU6819494A (en) 1993-04-26 1994-11-21 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
EP0714409A1 (en) 1993-06-16 1996-06-05 Celltech Therapeutics Limited Antibodies
CA2109377C (en) * 1993-07-23 1998-08-04 Joseph C. Kahr Disc brake shoe assembly
AU1866895A (en) 1994-01-04 1995-08-01 Scripps Research Institute, The Human monoclonal antibodies to herpes simplex virus and methods therefor
ES2281899T3 (es) * 1994-05-06 2007-10-01 Institut Gustave Roussy Fracciones polipeptidicas solubles de la proteina lag-3; procedimiento de produccion; composicion terapeutica; anticuerpo anti-idiotipo.
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6410690B1 (en) 1995-06-07 2002-06-25 Medarex, Inc. Therapeutic compounds comprised of anti-Fc receptor antibodies
JP2000508226A (ja) * 1995-07-21 2000-07-04 アプライド リサーチ システムズ アース ホールディング エヌ．ヴィ． Ｌａｇ−３タンパク質によるｔｈ１リンパ球を検出、同定、単離並びに選択的に標識およびターゲッティングする方法
US5811097A (en) 1995-07-25 1998-09-22 The Regents Of The University Of California Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
KR19990087557A (ko) * 1996-03-07 1999-12-27 그윈넬 해리 제이 근적외선 형광 비밀정보의 열전사 인쇄 및 표시용 리본
US5922845A (en) 1996-07-11 1999-07-13 Medarex, Inc. Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies
WO1998023741A1 (fr) * 1996-11-28 1998-06-04 Institut Gustave Roussy Mutants de la proteine lag-3, leur expression et utilisation
WO1998023748A1 (en) * 1996-11-29 1998-06-04 Applied Research Systems Ars Holding N.V. Methods for preventing graft rejection in transplantation and for producing a universal gene therapy host cell using lymphocyte activation (lag-3)
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
JP2001523958A (ja) 1997-03-21 2001-11-27 ブライハム アンド ウィミンズ ホスピタル，インコーポレイテッド 免疫療法のｃｔｌａ−４結合ペプチド
GB2339430A (en) 1997-05-21 2000-01-26 Biovation Ltd Method for the production of non-immunogenic proteins
EP0900841A1 (en) 1997-06-18 1999-03-10 Institut National De La Sante Et De La Recherche Medicale (Inserm) LAG-3 splice variants
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
ES2340112T3 (es) 1998-04-20 2010-05-28 Glycart Biotechnology Ag Ingenieria de glicosilacion de anticuerpos para la mejora de la citotoxicidad celular dependiente de anticuerpos.
GB9814383D0 (en) 1998-07-02 1998-09-02 Cambridge Antibody Tech Improvements relating to antibodies
WO2000005266A1 (en) 1998-07-21 2000-02-03 Connex Gesellschaft Zur Optimierung Von Forschung Und Entwicklung Mbh Anti hepatitis c virus antibody and uses thereof
OA11917A (en) 1998-12-23 2006-04-13 Abgenix Inc Human monoclonal antibodies to ctla-4.
WO2000042072A2 (en) 1999-01-15 2000-07-20 Genentech, Inc. Polypeptide variants with altered effector function
US6914128B1 (en) 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
EP1176195B1 (en) 1999-04-09 2013-05-22 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
GB9911569D0 (en) * 1999-05-18 1999-07-21 Oxford Biomedica Ltd Antibodies
ATE384744T1 (de) 1999-07-29 2008-02-15 Medarex Inc Menschliche antikörper gegen her2/neu
PL354286A1 (en) 1999-08-23 2003-12-29 Dana-Farber Cancer Institutedana-Farber Cancer Institute Pd-1, a receptor for b7-4, and uses therefor
CA2589418A1 (en) 1999-08-24 2001-03-01 Medarex, Inc. Human ctla-4 antibodies and their uses
US7605238B2 (en) * 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
US6794132B2 (en) 1999-10-02 2004-09-21 Biosite, Inc. Human antibodies
KR20120053525A (ko) * 2000-06-16 2012-05-25 캠브리지 안티바디 테크놀로지 리미티드 면역특이적으로 ＢＬｙＳ에 결합하는 항체
US6818216B2 (en) 2000-11-28 2004-11-16 Medimmune, Inc. Anti-RSV antibodies
US7041870B2 (en) 2000-11-30 2006-05-09 Medarex, Inc. Transgenic transchromosomal rodents for making human antibodies
EP1401866A2 (en) * 2001-02-22 2004-03-31 Institut Pasteur Comparative mycobacterial genomics as a tool for identifying targets for the diagnosis, prophylaxis or treatment of mycobacterioses
US20020146753A1 (en) * 2001-04-06 2002-10-10 Henrik Ditzel Autoantibodies to glucose-6-phosphate isomerase and their participation in autoimmune disease
AU2002309063B8 (en) 2001-05-11 2008-04-24 Kyowa Kirin Co., Ltd. Artificial human chromosome containing human antibody lambda light chain gene
JP2004532038A (ja) 2001-05-17 2004-10-21 ディヴァーサ コーポレイション 新規抗原結合分子の治療、診断、予防、酵素、産業ならびに農業各分野への応用とそのための新規抗原結合分子の作製とスクリーニングの方法
CN1463270A (zh) 2001-05-31 2003-12-24 梅达莱克斯公司 细胞毒素、其有用的前体药物、连接基团和稳定剂
DK1436404T3 (da) * 2001-09-19 2010-03-08 Alexion Pharma Inc Manipulerede templates og deres anvendelse i single-primer amplifikation
ATE519779T1 (de) * 2001-09-19 2011-08-15 Roussy Inst Gustave An das glu-pro motiv-bindende proteine und peptide, diese enthaltende therapeutische zusammensetzungen und deren anwendungen
WO2003035835A2 (en) 2001-10-25 2003-05-01 Genentech, Inc. Glycoprotein compositions
EP1575480A4 (en) 2002-02-22 2008-08-06 Genentech Inc COMPOSITIONS AND METHODS FOR TREATING DISEASES RELATED TO THE IMMUNE SYSTEM
AU2003217912A1 (en) 2002-03-01 2003-09-16 Xencor Antibody optimization
PL373256A1 (en) 2002-04-09 2005-08-22 Kyowa Hakko Kogyo Co, Ltd. Cells with modified genome
NZ535925A (en) 2002-04-16 2008-06-30 Genentech Inc An isolated antibody that binds to a particular polypeptide
DK2206517T3 (da) 2002-07-03 2023-11-06 Ono Pharmaceutical Co Immunpotentierende sammensætninger omfattende af anti-PD-L1-antistoffer
EP2322201A3 (en) 2002-10-29 2011-07-27 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
WO2005035732A2 (en) * 2003-02-19 2005-04-21 Dyax Corporation Papp-a ligands
SI1897548T1 (sl) 2003-02-28 2013-12-31 The Johns Hopkins University Regulacija celic T
CA2536807C (en) 2003-09-04 2010-07-13 Medarex, Inc. Expression vector
WO2005034733A2 (en) * 2003-10-08 2005-04-21 North Shore-Long Island Jewish Research Institute Methods and compositions for diagnosis and treatment of b cell chronic lymphocytic leukemia
CA2561533C (en) * 2004-04-13 2015-06-16 Yvo Graus Anti-p-selectin antibodies
WO2005103081A2 (en) * 2004-04-20 2005-11-03 Genmab A/S Human monoclonal antibodies against cd20
NZ550934A (en) 2004-05-19 2010-05-28 Medarex Inc Chemical linkers and conjugates thereof
US7691962B2 (en) 2004-05-19 2010-04-06 Medarex, Inc. Chemical linkers and conjugates thereof
MX2007000644A (es) * 2004-07-20 2007-03-28 Symphogen As Anticuerpo policlonal recombinante anti-rhesus d y metodos de fabricacion.
EP1807451A2 (en) * 2004-08-03 2007-07-18 Dyax Corporation Hk1-binding proteins
US20090252741A1 (en) * 2004-09-08 2009-10-08 Ohio State University Research Foundation Human monoclonal anti-ctla4 antibodies in cancer treatment
KR20070083899A (ko) * 2004-10-01 2007-08-24 메다렉스, 인코포레이티드 Ｃｄ30 양성 림프종의 치료 방법
HUE039237T2 (hu) 2004-10-06 2018-12-28 Mayo Found Medical Education & Res B7-H1 és PD-1 vesesejt karcinoma kezelésében
CA2598454C (en) 2005-02-18 2013-04-09 Medarex, Inc. Monoclonal antibodies against prostate specific membrane antigen (psma) lacking in fucosyl residues
MX2007010603A (es) 2005-03-23 2007-10-18 Pfizer Prod Inc Terapia de cancer de prostata con anticuerpos contra ctla4 y terapia hormonal.
US7714016B2 (en) 2005-04-08 2010-05-11 Medarex, Inc. Cytotoxic compounds and conjugates with cleavable substrates
DK2161336T4 (en) 2005-05-09 2017-04-24 Ono Pharmaceutical Co Human monoclonal antibodies for programmed death 1 (PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapies
EP3130350A1 (en) * 2005-06-08 2017-02-15 Dana-Farber Cancer Institute, Inc. Methods and compositions for the treatment of persistent infections and cancer by inhibiting the programmed cell death 1 (pd-1)pathway
AU2006265108C1 (en) 2005-07-01 2013-01-17 E. R. Squibb & Sons, L.L.C. Human monoclonal antibodies to programmed death ligand 1 (PD-L1)
AU2006294554B2 (en) 2005-09-26 2013-03-21 E. R. Squibb & Sons, L.L.C. Antibody-drug conjugates and methods of use
KR20080068084A (ko) 2005-10-26 2008-07-22 메다렉스, 인코포레이티드 씨씨-1065 유사체를 제조하기 위한 방법 및 화합물
US8679490B2 (en) * 2005-11-07 2014-03-25 Genentech, Inc. Binding polypeptides with diversified and consensus VH/VL hypervariable sequences
WO2007059404A2 (en) 2005-11-10 2007-05-24 Medarex, Inc. Duocarmycin derivatives as novel cytotoxic compounds and conjugates
EP1966241A2 (en) * 2005-12-05 2008-09-10 Symphogen A/S Anti-orthopoxvirus recombinant polyclonal antibody
WO2008007648A1 (fr) * 2006-07-10 2008-01-17 Institute For Antibodies Co., Ltd. Procédé de classification d'antigène, procédé d'identification d'antigène, procédé d'obtention d' un ensemble d'antigènes ou d'anticorps, procédés de construction d'un panel d'anticorps, anticorps et ens
WO2008073160A2 (en) 2006-08-17 2008-06-19 The Trustees Of Columbia University In The City Of New York Methods for converting or inducing protective immunity
CL2007003622A1 (es) 2006-12-13 2009-08-07 Medarex Inc Anticuerpo monoclonal humano anti-cd19; composicion que lo comprende; y metodo de inhibicion del crecimiento de celulas tumorales.
TWI412367B (zh) 2006-12-28 2013-10-21 Medarex Llc 化學鏈接劑與可裂解基質以及其之綴合物
CN101616911A (zh) 2007-02-21 2009-12-30 梅达莱克斯公司 具有单个氨基酸的化学连接物及其偶联物
EP1987839A1 (en) 2007-04-30 2008-11-05 I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
US20090028857A1 (en) * 2007-07-23 2009-01-29 Cell Genesys, Inc. Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof
PT2201100E (pt) * 2007-09-14 2016-06-03 Univ Brussel Vrije Aperfeiçoamento da capacidade estimulatória de células t das células que apresentam antígeno humano e o seu uso na vacinação
CA2700860C (en) 2007-10-01 2016-07-19 Jonathan A. Terrett Human antibodies that bind mesothelin, and uses thereof
KR20100093578A (ko) 2007-11-30 2010-08-25 브리스톨-마이어스 스큅 컴퍼니 항-비7에이취4 단일클론 항체-약물 접합체 및 그 사용 방법
MX2010005966A (es) 2007-11-30 2010-06-15 Bristol Myers Squibb Co Conjugados de anticuerpo monoclonal-molecula asociada dirigidos a la proteina tirosina-cinasa 7 (ptk7).
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
CN113967253A (zh) 2012-05-15 2022-01-25 百时美施贵宝公司 通过破坏pd-1/pd-l1信号传输的免疫治疗
AR091649A1 (es) 2012-07-02 2015-02-18 Bristol Myers Squibb Co Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos
EA201792273A1 (ru) 2015-04-17 2018-04-30 Бристол-Маерс Сквибб Компани Композиции, содержащие комбинацию анти-pd-1 антитела и другого антитела
KR20180042412A (ko) 2015-09-02 2018-04-25 이뮤텝 에스.에이.에스. 항-lag-3 항체
TWI756187B (zh) 2015-10-09 2022-03-01 美商再生元醫藥公司 抗ｌａｇ３抗體及其用途

Also Published As

Publication number Publication date
DK3597216T3 (da) 2022-10-31
CN113773386A (zh) 2021-12-10
AR115072A2 (es) 2020-11-25
CL2013002062A1 (es) 2014-01-10
PE20190373A1 (es) 2019-03-08
KR101700459B1 (ko) 2017-01-26
LT3597216T (lt) 2022-11-10
ES2768576T3 (es) 2020-06-23
AR117774A2 (es) 2021-08-25
IL253868A0 (en) 2017-10-31
EP3597216A1 (en) 2020-01-22
EA201590777A1 (ru) 2016-01-29
AU2009282134B2 (en) 2014-07-03
US10344089B2 (en) 2019-07-09
CY1122576T1 (el) 2021-01-27
AU2009282134A1 (en) 2010-02-18
ZA201101009B (en) 2012-11-28
SI2320940T1 (sl) 2015-07-31
US11512130B2 (en) 2022-11-29
SG10201706497QA (en) 2017-09-28
US20200231671A1 (en) 2020-07-23
HRP20221191T1 (hr) 2022-12-09
AU2014221286A1 (en) 2014-10-02
DK2320940T3 (en) 2015-05-26
BRPI0917470B8 (pt) 2021-05-25
US11001630B2 (en) 2021-05-11
CA2734335C (en) 2018-01-16
JP2021091696A (ja) 2021-06-17
PT2320940E (pt) 2015-06-19
EP2905030A1 (en) 2015-08-12
CO6351751A2 (es) 2011-12-20
US11236163B2 (en) 2022-02-01
PT3597216T (pt) 2022-09-28
JP2017052765A (ja) 2017-03-16
CN103923213A (zh) 2014-07-16
CA2734335A1 (en) 2010-02-18
PE20141658A1 (es) 2014-11-08
MX2019000094A (es) 2023-04-12
JP2015096503A (ja) 2015-05-21
HK1212911A1 (zh) 2016-06-24
US20200385467A1 (en) 2020-12-10
HUE025250T2 (en) 2016-02-29
BRPI0917470B1 (pt) 2020-09-24
HUE060029T2 (hu) 2023-01-28
US20180066054A1 (en) 2018-03-08
KR20190000922A (ko) 2019-01-03
JP2012500006A (ja) 2012-01-05
HRP20200070T1 (hr) 2020-04-03
CL2016002624A1 (es) 2017-06-09
DK2905030T3 (da) 2020-02-17
EA201100340A1 (ru) 2011-08-30
KR20170010901A (ko) 2017-02-01
AR072999A1 (es) 2010-10-06
US10988536B2 (en) 2021-04-27
LT2905030T (lt) 2020-02-10
EP2320940A2 (en) 2011-05-18
TW201019958A (en) 2010-06-01
US20210261662A1 (en) 2021-08-26
PE20110306A1 (es) 2011-05-21
CL2011000308A1 (es) 2011-05-27
CN102176921A (zh) 2011-09-07
HK1151985A1 (en) 2012-02-17
KR20200068749A (ko) 2020-06-15
ES2537203T3 (es) 2015-06-03
US11530267B2 (en) 2022-12-20
US11236165B2 (en) 2022-02-01
PL2320940T3 (pl) 2015-08-31
US20220204612A1 (en) 2022-06-30
KR20230165352A (ko) 2023-12-05
NZ602780A (en) 2014-04-30
EP4147714A1 (en) 2023-03-15
EP2905030B1 (en) 2019-11-06
JP2023113722A (ja) 2023-08-16
CN102176921B (zh) 2014-05-07
US20190276539A1 (en) 2019-09-12
PL2905030T3 (pl) 2020-04-30
US20200385466A1 (en) 2020-12-10
HRP20200070T8 (hr) 2021-03-05
KR102121141B1 (ko) 2020-06-10
IL261718A (en) 2018-10-31
EP2320940A4 (en) 2013-01-23
SMT201500125B (it) 2015-07-09
IL210731A (en) 2017-08-31
CN107474137A (zh) 2017-12-15
CL2018001903A1 (es) 2018-11-09
TN2011000025A1 (en) 2012-09-05
US20110150892A1 (en) 2011-06-23
JP5647981B2 (ja) 2015-01-07
SI2905030T1 (sl) 2020-02-28
US11236164B2 (en) 2022-02-01
NZ590991A (en) 2012-11-30
NZ623319A (en) 2015-08-28
IL210731A0 (en) 2011-03-31
PT2905030T (pt) 2020-01-29
EP2320940B1 (en) 2015-03-04
US20210261661A1 (en) 2021-08-26
US20190276538A1 (en) 2019-09-12
KR102370201B1 (ko) 2022-03-04
ES2927547T3 (es) 2022-11-08
US10988535B2 (en) 2021-04-27
IL281876A (en) 2021-05-31
EA023032B1 (ru) 2016-04-29
US20210261660A1 (en) 2021-08-26
JP7286692B2 (ja) 2023-06-05
MX2011001250A (es) 2011-03-29
JP2019030307A (ja) 2019-02-28
WO2010019570A3 (en) 2010-06-17
KR20110050507A (ko) 2011-05-13
TWI491408B (zh) 2015-07-11
CY1116582T1 (el) 2017-03-15
KR20220032636A (ko) 2022-03-15
US20220195040A1 (en) 2022-06-23
US20230322919A1 (en) 2023-10-12
PL3597216T3 (pl) 2022-11-14
WO2010019570A2 (en) 2010-02-18
EP3597216B1 (en) 2022-08-24
HRP20150453T1 (hr) 2015-06-19

Similar Documents

Publication Publication Date Title
BRPI0917470A2 (pt) anticorpos humanos que se ligam ao gene de ativação linfocitária-3(lag) e usos dos mesmos
HUS2300002I1 (hu) Emberi antitest optimálása, amelyek limfocita aktivációs Gén-3-at (LAG-3) kötnek és azok felhasználása
BRPI0821658A2 (pt) Anticorpos contra nkg2d humano e usos dos mesmos
BRPI0819909A2 (pt) anticorpos antimesotelina e usos dos mesmos
BRPI0912198A2 (pt) anticorpos anti-fn14 e usos dos mesmos
CY2017043I2 (el) Anti-pd-l1 αντισωματα και χρηση αυτων για την ενισχυση της λειτουργιας τ-κυτταρων
BRPI1009455A2 (pt) anticorpos anti-c40 e usos dos mesmos
IL230771A (en) Antibody from a person that binds pcsk9
CY2015058I1 (el) Αντισωματα προς ανθρωπινο προγραμματισμενου θανατου υποδοχεα pd-1
BRPI0916443A2 (pt) anticorpos de neutralização de citomegalovírus humanos e uso dos mesmos
BRPI1012340A8 (pt) proteínas de ligação específica e usos das mesmas
BRPI0913656A2 (pt) anticorpos anti-cdh3 marcados com marcador radioisótopo e usos dos mesmos
BRPI0919531A2 (pt) anticorpos contra il17 humana e usos dos mesmos
BRPI0918868A2 (pt) moduladores do receptor de nmda e usos dos mesmos
BRPI0822989A2 (pt) anticorpos de neutralização de citomegalovíorus humano e uso dos mesmos
BRPI0919853A2 (pt) anticorpos humanos de alta afinidade para receptor il-4 humano
BRPI0908259A2 (pt) Materiais biológicos e usos dos mesmos
BRPI0814119A2 (pt) Método de análise de diafragma e uso dos produtos obtidos de acordo com o método
BRPI0919411A2 (pt) derivado de glicosídeo e usos dos mesmos
FR2942231B1 (fr) Acides nucleiques se liant specifiquement au facteur vii/viia humain, et utilisations
TH0601001328A (th) การเสริมการปล่อยสารที่ให้ประโยชน์ของผิวหนัง
TH124710B (th) สารภูมิต้านทานต้าน il17 ของมนุษย์ และการใช้ของสารเหล่านั้น

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: MEDAREX, L.L.C. (US)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B25A Requested transfer of rights approved

Owner name: E.R. SQUIBB AND SONS, LLC (US)

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 24/09/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 11/08/2009 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF